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ABSTRACT 
An influenza A virus (IAV) vaccine that provides better cross protection to pigs 
against heterologous strain infection and overrides maternal antibodies interference is 
desirable. A replicon particle (RP) platform has been developed for influenza vaccine for 
swine use by expressing influenza proteins. 
Chapter 2 presented a review of influenza virus infection in swine, including a 
discussion of current vaccine approaches and techniques used for novel vaccine 
development.  
The first animal study (Chapter 3), composing two experiments, demonstrated the 
efficacy of intranasal (IN) administration of RP expressing hemagglutin (HA) protein (HA 
RP) of Pandemic H1N1 (A/CA/04/2009) strain. Prime/boost HA RP vaccination was 
administered IN/IN to pigs, with IM/IM administration as positive control and sham 
vaccination as negative control (five pigs each group). All pigs were challenged by 
homologous challenge following two doses vaccination. Pigs were not protected by IN/IN 
administration of RP against IAV challenge. Virus titers and pneumonia were not reduced 
significantly in RP IN/IN administered group, compared with control group. In the second 
experiment, pigs were administered with one dose HA RP vaccine IM or IN, or with a 
combination of IN/IM routes with an interval of three weeks. At most, two pigs at 2 DPC and 
3 DPC, and no pigs at 3 DPC to 5DPC in IN/IM or one dose IM administered pigs were 
isolated with live virus, while all five pigs were detected with live virus from one dose RP IN 
administered pigs and sham vaccinated pigs. We also found that one dose IM and 
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combination of IN/IM vaccination with HA RP reduced pneumonia significantly compared 
with sham vaccinated group, contrary to one dose IN vaccination. 
In the second animal study (Chapter 4), the immunogenicity of HA RPs of a H3N2 
strain and a delta1 strain at varying doses [1×107 (infectious unit) IU to 5×105 IU], was 
evaluated. Two H3N2 RP vaccinated groups with 106 IU or 5×105 IU RP as negative control, 
and two delta1 RP vaccinated groups with 106 IU or 5×105 IU RP were all challenged with 
delta1 IAV virus homologous to delta1 RP. RPs at 5×105 IU or higher doses tested in this 
study were sufficient to induce hemagglutinnin inhibition (HI) detectable antibodies. HI titers 
were greater at increasing vaccine doses. Delta1 RP 106 IU or 5×105 IU doses, which induced 
HI antibodies with mean titers equal to or lower than 20, partially prevent homologous 
infection by eliminating virus replication in lung at day 5 post challenge. However, compared 
with H3N2 RP vaccinated pigs, decreased lung lesions observed in delta1 RP vaccinated pigs 
were not statistically significant. 
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CHAPTER 1. INTRODUCTION: THESIS ORGANIZATION 
This thesis consists five chapters. Chapter 1 is an introduction of the thesis organization. 
Chapter 2 is a review of literature, “Vaccine development for protecting swine against 
influenza virus”. The manuscript will be submitted to Animal Health Research Reviews. 
Chapter 3 are composed of two animal experiments, evaluating the efficacy of replicon 
particles (RP) by immunizing pigs intranasally. Chapter 4 determined RP vaccine of delta1 
subtype dose, hemagglutinin inhibition and challenge responses. The last chapter is a general 
conclusion of the entire thesis research. 
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CHAPTER 2. VACCINE DEVELOPMENT FOR PROTECTING SWINE 
AGAINST INFLUENZA VIRUS 
A manuscript to be submitted to Animal Health Research Reviews 
Qi Chen, Darin Madson, Cathy L. Miller, D.L. Hank Harris 
Abstract 
Influenza virus infects a wide variety of species including humans, pigs, horses, sea 
mammals and birds. Weight loss caused by influenza infection and/or co-infection with other 
infectious agents results in significant financial loss in swine herds. The emergence of 
Pandemic H1N1 (A/CA/04/2009/H1N1), which infects both humans and livestock caused 
pandemic disease and brought about a concerning public health threat. Influenza virus 
contains eight single stranded, negative-sense RNA genome segments. This genetic structure 
allows the virus to evolve rapidly by antigenic drift and shift. Antigen specific antibodies 
induced by current vaccines provide limited cross protection to heterologous challenge. In 
pigs, this presents a major obstacle for vaccine development. Different strategies are under 
development to produce vaccines that provide better cross-protection for swine. Moreover, 
overriding interfering maternal antibodies is another goal for influenza vaccines in order to 
immunize piglets at an early age. Herein, we present a review of influenza virus infection in 
swine, including a discussion of current vaccine approaches and techniques used for novel 
vaccine development.  
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Influenza in swine 
Influenza is a zoonotic disease caused by influenza virus which infects a wide variety 
of species including humans, pigs, horses, sea mammals and birds. Influenza virus was first 
isolated in the United States in 1930 (Shope 1931) and transmission between species happens 
occasionally (Vincent et al. 2008a). Sero-archeological studies of human samples from 1918 
to 1920 showed the original causative virus of the 1918 pandemic flu was closely related to 
influenza virus A/Swine/Iowa/30 (H1N1) strain which is now referred to as classic H1N1 
(cH1N1) (Webster 1999). 
Viral characteristics 
Influenza virus belongs to the family Orthomyxoviridae. Three types of influenza 
virus, type A, B and C, are grouped based on antigenic characteristics of the nucleoprotein 
(NP) (Mahy, 1997; Alexander and Brown, 2000a). Pathogenic influenza viruses in domestic 
animals are type A viruses (Maclachlan and Dubovi, 2011). Influenza A viruses (IAV) are 
enveloped with a size of around 80-120 nm and possess eight single stranded, negative-sense 
RNA genome segments packaged within virions (Maclachlan and Dubovi, 2011). Eleven 
proteins are encoded by these eight segments, including hemagglutinin (HA), neuraminidase 
(NA), matrix protein 1 (M1) and 2 (M2), polymerase basic 1(PB1) and 2 (PB2), NP, 
polymerase acidic (PA), PB1-F2 and nonstructural protein 1 (NS1) and 2 (NS2) (Maclachlan 
and Dubovi, 2011). Structural proteins HA, NA, M1 and M2 form the envelope of IAV with 
the cellular lipid bilayer. HA protein plays a critical role during IAV cell entry. HA 
attachment to permissive cell sialic acid receptor on the plasma membrane initiates virus 
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entry cells via receptor-mediated endocytosis (Murphy et al., 1999). NA also binds to cell 
receptor sialic acid. During mature progeny virus detaching from host cells, the binding of 
NA and sialic acid on the same host cell prevents progeny virus self aggregation back to the 
same host cell mediated by HA (Grienke et al., 2012). In addition, the surface glycoproteins 
HA and NA induce protective specific immune responses in the host, but are not highly 
conserved (Alexander and Brown, 2000). At present, 16 distinct HA antigenic subtypes and 9 
NA subtypes are identified (Bouvier and Palese, 2008) allowing further sub-typing according 
to the combination of HA and NA proteins present on the virion surface.  
PB1, PB2 and PA form a trimeric RNA polymerase complex that binds one end of 
RNA segments and forms ribonucleoprotein (RNP) complexes with NP (Klumpp et al., 
1997). RNP is required to transcribe positive strand mRNA and complementary cRNA, 
because negative strand RNAs cannot serve as translation templates directly (Baltimore et al., 
1970; Conzelmann, 1998). Segments 7 and 8 encode two proteins respectively (M1and M2, 
NS1and NS2) by differential splicing of mRNAs (Backstrom et al., 2011). NS1 protein plays 
multiple roles during viral replication and is not incorporated in progeny virus (Hale et al., 
2008; Shaw et al., 2008; Matsuda et al., 2010; Nivitchanyong et al., 2011). For example, NS1 
interacts with phosphorylated serine threonine kinase Akt in cells and enhances Akt 
promoting anti-apoptotic activity (Matsuda et al., 2010). NS1also inhibits interferon 
production and antiviral effects subsequently induced by interferon, and enhances viral 
protein translation is related with NS1 (Hale et al., 2008).  NS2 is also known as nuclear 
export protein (NEP) (Shaw et al., 2008). Both M1 and NS2 are involved in mediating export 
of RNPs from the nucleus (O'Neill et al., 1998; Akarsu et al., 2011). M2 tetramers in the 
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virus capsid serve as ion channels after virion entry into the endosome. Changes in 
endosomal pH cause a conformational change in HA which allows fusion with the 
endosomal membrane. In an independent event, M2 pumps protons into the virion which 
causes M1 (which is tightly associated with the RNPs) to release the RNPs so they can traffic 
to and enter the nucleus (Wang et al., 1993; Maclachlan and Dubovi, 2011). M2 has an 
extracellular domain (M2e) which has been considered a potential vaccine component 
(Neirynck et al., 1999). Since influenza is an enveloped virus, antibodies can only easily bind 
to protein domains spiking out of the virus membrane. HA, NA and M2 proteins all have 
extracellular domains outside of the virus membrane. These three proteins all have the 
potential to be vaccine targets to induce humoral responses. 
Swine IAV disease 
When pigs are infected with IAV, an acute disease in the respiratory tract is 
manifested similar to human infection. The incubation period of disease is 1 to 3 days 
followed by sudden disease onset of clinical signs and recovery. Recovery usually occurs 
within 7 to 10 days following infection (Vincent et al., 2008a). High morbidity and low 
mortality rates are observed by most swine IAV strains (Vincent et al., 2008a). Characterized 
clinical signs include fever, respiratory distress, coughing, sneezing, labored breathing, 
anorexia, and prostration (Richt et al., 2003; Ma et al. 2011). Purple to red multifocal or 
coalescing consolidated areas occur in cranio-ventral lung lobes are generally seen as gross 
lesions (Richt et al., 2003; Vincent et al., 2008a). Acute epithelial necrosis with subsequent 
attenuation or reactive proliferation, bronchointerstitial pneumonia, atelectasis, bronchiolitis, 
proteinaceous fluid and peribronchiolar lymphocytic infiltration are typical microscopic 
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changes within the lung (Richt et al., 2003; Vincent et al., 2008a; Ma et al., 2009; Ma et al., 
2011). Virus shedding can be detected from nasal swabs and bronchoalveolar lavage (BAL) 
fluids. Young pigs are more susceptible to IAV than adult pigs (Richt et al., 2003). IAV co-
infection with Mycoplasma hyopneumoniae, porcine reproductive and respiratory syndrome 
virus (PRRSV), and porcine circovirus type 2 (PCV2) and secondary bacterial infection in 
the respiratory tract of pigs is known as porcine respiratory disease complex (PRDC) 
(Thacker et al., 2001; Ellis et al., 2004; Fablet et al., 2011). 
Swine IAV subtypes 
IAV evolves continuously in two ways termed antigenic drift and antigenic shift. 
Minor changes of HA and NA proteins constitute antigenic drift including point mutations of 
nucleotides, i.e., substitutions, insertions and deletions (Murphy et al., 1999). Such minor 
mutations are due to polymerase errors which are common in RNA virus replication 
(Domingo et al., 1998; Gauger and Vincent, 2011). Antigenic drift may result in HA and NA 
types that are not recognized by antibodies induced prior to mutation. Antigenic shift 
constitutes major changes of gene combination or reassortment caused by exchange of whole 
gene segments between different strains which co-infect the same animal (Murphy et al., 
1999; Vincent et al., 2008a). These two mechanisms of evolution give rise to the emergence 
of variant viruses. Pigs are susceptible to challenge of many subtypes of IAV (Kida et al., 
1994). Before 1998, cH1N1 was the predominant subtype that caused most influenza 
infection in swine and had a predictable pattern similar to human influenza with prevalence 
in late fall and early winter (Easterday and Van Reeth, 2007). In 1998, an influenza outbreak 
in swine herds happened in several US states. The causative subtype was identified as H3N2 
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(Vincent et al., 2008a), a triple reassortant of gene segments from human-like H3N2 HA, 
NA, PB1 genes, avian-like PB2 and PA genes and cH1N1-like NS, NP, and M genes (Zhou 
et al., 1999; Webby et al., 2000). With time, triple reassortant H3N2 mutated and reassorted 
with cH1N1 to form new genotypes including new clusters of H3N2, H1N2 (HA from 
cH1N1 and other segments from H3N2), H3N1 and reassortant H1N1 (rH1N1, HA and NA 
from cH1N1 and other segments from H3N2) (Choi et al., 2002; Richt et al., 2003; Webby et 
al., 2004). Reassortment of H3N2 with HA and NA from human virus lineages H1N1 and 
H1N2 form huH1N1 and huH1N2 have been reported as spreading in US swine herds 
(Vincent et al., 2009; Lorusso et al., 2011). Within the H3N2 subtype, there are 4 
phylogenetic clusters of H3N2 strain: I, II, III and IV (Richt et al., 2003; Hause et al., 2010; 
Olsen et al., 2006). Four phylogenetic clusters of swine H1 subtype have been identified in 
America: α (cΗ1Ν1), β (rΗ1Ν1), δ (huH1N1, huH1N2) and γ (H1N2), other than pandemic 
H1N1 (pH1N1) which forms clusters separated from North American viruses; cluster δ can 
be differentiated into two subclusters, δ1 (huH1N2) and δ2 (huH1N1) (Lorusso et al., 2011). 
MA and NA genes from Eurasian IAV reassorted with North American triple reassortant 
virus resulted in pandemic H1N1 (pH1N1), which caused disease in both humans and swine 
in 2009 (Garten et al., 2009; Moreno et al., 2010). Further reassortment of H3N2 and pH1N1 
resulting in new IAV strains has been reported in Canadian swine in 2010 (Tremblay et al., 
2011).  
The main subtypes of IAV circulating in North American swine are H1N1, H1N2 and 
the H3N2 Cluster IV (Richt et al., 2003; Vincent et al., 2009; Kumar et al., 2011). According 
to the data from 2001 to 2007 of University of Minnesota Veterinary Diagnostic Laboratory, 
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in H1 subtypes, cluster α has been replaced with clusters β, δ and γ, and cluster IV became 
dominant in H3N2 subtypes (Rapp-Gabrielson et al., 2008). After the emergence of the 
pH1N1 subtype, the prevalence of pH1N1 in swine became significant. According to data 
from University of Minnesota Veterinary Diagnostic Laboratory, of all IAV isolates from 
swine in 2010, 27.8% were H3N2 cluster IV, 22.4% were pH1N1, 18% were huH1N2 δ1, 
9% were huH1N1 δ2, 15.7% was H1N1 γ and the percentage of isolates belonging to α, β 
and other H3N2 clusters was less than 10% (Pfizer Inc., 2012). Influenza viruses of different 
clusters are antigenically divergent (Lorusso et al., 2011). Serologically, there is moderate to 
good HA antibody-antigen cross-reactivity between classical H1 and reassortment H1cluster 
β and H1cluster γ, but limited cross-reactivity among cluster β, γ and δ, or within δ cluster 
(Vincent et al., 2006; Vincent et al., 2008a; Vincent et al., 2009; Lorusso et al., 2011). For 
H3N2 IAV, cluster I and III, but not II, have HA antibody-antigen cross-reactivity between 
each cluster, and good reactivity within each cluster (Richt et al., 2003). The limited cross-
reactivity of HA antibodies to HA antigens between different subtypes and clusters is one of 
the obstacles in developing vaccines to prevent all IAV viruses infecting swine.  
Immune Responses of Influenza Infection in Swine 
Influenza virus infection induces both cellular and humoral responses. Soluble 
effectors including cytokines are secreted as a part of the innate immune response to IAV 
infection. Pro-inflammatory cytokines, including interferon α (IFN-α), tumor necrosis factor-
α (TNF-α), and interleukin-1 (IL-1), are secreted in the lung associated with virus titers in 
pigs infected by IAV  (Van Reeth, 2000). Cellular-mediated immune responses participate in 
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protecting swine from IAV infection. Proliferation of cross-reactive memory T-cells were 
detected in IAV recovered pigs that were free of maternal antibodies during infection, but not 
those with maternal antibodies present during infection (Kitikoon et al., 2006). IAV infected 
pigs with reactive memory T-cells recovered faster than those without such memory T-cells, 
so the presence of these cells in pigs may participate in rapid recovery from IAV infection 
(Kitikoon et al., 2006).  
In adaptive humoral immunity, systemic and mucosal immune responses are induced 
following IAV infection, both of which are essential for the prevention and recovery from 
IAV infection (Cox et al., 2004). IAV specific IgG and IgA antibodies are believed to 
significantly contribute to virus clearance. Antibodies against HA are the most important in 
preventing infection, although, antibodies against NA contribute as well (Ma and Richt, 
2010). Testing HI antibody titers in serum has been used widely to predict humoral immune 
response and protection against IAV infection because vaccinated pigs are protected from 
IAV infection by high HI antibody titers (Larsen et al., 2000;Vander Veen et al., 2009). 
Furthermore, testing HI titer in serum to different IAV virus subtypes can predict cross-
protection efficacy. Because IAV targets mucosal cells in the respiratory tract, antibodies 
need to be transported to mucosal sites. Short-lived serum IgG antibodies and more durable 
local IgA antibodies occur in pigs recovering from influenza infection or when vaccinated 
via a mucosal route. These protected pigs from further IAV challenge (Charley et al., 2006). 
Virus specific IgG and IgA, as well as HI antibodies, peaked at 2 to 3 weeks after primary 
IAV infection in pigs.  IgG is predominant in serum and IgA is predominant in the 
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respiratory tract (Larsen et al., 2000). IgA or IgG secreting cells in nasal mucosa are 
dramatically higher in numbers than that in any other tissues (Larsen et al., 2000).  
Swine Influenza Vaccines  
Vaccination can be an effective way to decrease IAV infection and reduce economic 
losses due to influenza pneumonia.  
“There are three major problems with the control and prevention of SI 
in the U.S.: (a) SIV is changing faster than traditional vaccines can be 
developed, (b) There is a need for vaccines that can induce better 
crossprotection among SIV isolates, and (c) Passively acquired immunity is 
believed to block vaccine efficacy in pigs” (Vincent et al., 2008a).  
Similar point of view was indicated in another paper (Ma and Richt, 2010). 
Nevertheless, different types of IAV vaccine and strategies have been developed in order 
approach this aim (Table 1).  
Inactivated virus vaccines 
Commercial inactivated IAV vaccine for swine use became available in 1994 
(Vincent et al., 2008a; Platt et al., 2011). Currently, inactivated whole virus IAV vaccine is 
the only commercially available vaccine used worldwide in swine herds (Ma and Richt, 
2010). While inactivated whole virus IAV vaccines protect pigs fully against homologous 
IAV challenge, they only partially protect pigs against heterologous challenge (Vincent et al., 
2010a; Vincent et al., 2010b). 
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To manufacture inactivated IAV, embryonated hen’s eggs are generally used to 
propagate live virus (Gorres et al., 2011). Live virus is harvested from the eggs and killed 
with chemical treatment (Sanofi pasteur, 2009). Since frequent antigenic shift and drift of 
IAV occurs and older vaccines do not protect the infection of current circulating viruses, 
regulatory procedure for updating IAV strains in United States Department of Agriculture 
(USDA)-licensed veterinary vaccines is allowed to be expedited by USDA (Rapp-Gabrielson 
et al., 2008). It currently takes at least one year to update a commercial IAV vaccine (D.L. 
Harris, Iowa State University, personal communication). The approval of changing virus 
strains in vaccines is based on the efficacy and safety demonstration (Rapp-Gabrielson et al., 
2008).  
The most common vaccination route of influenza vaccines is intramuscular injection 
(IM). Intramuscular vaccination induces a high level of specific IgG antibody in serum and 
lung but lacks cross protection to other virus strains of different subtypes (Heinen et al., 
2001). Immune responses of pigs naturally immunized by virus (A/Sw/Oedenrode/96 H3N2) 
infection or immunized by inactivated vaccine (A/Port Chalmers/1/73 H3N2, antigenic 
different from A/Sw/Oedenrode/96 H3N2) were compared post A/Sw/Oedenrode/96 
challenge by Heinen et al. (2001). Results showed serum HI antibody titer, virus neutralizing 
antibody titer and nucleoprotein specific IgG antibody titer developed by vaccinated pigs 
were similar or higher than naturally immune pigs. However, vaccinated pigs developed 
lower nasal IgA titer and lower cell-mediated immune responses than naturally immune pigs 
(Heinen et al., 2001). Protection by this A/Port Chalmers/1/73 derived vaccine to 
A/Sw/Oedenrode/96 challenge was sub-optimal, because virus shedding was detected for a 
12 
short period in vaccinated pigs compared with no virus shedding from naturally immune pigs 
(Heinen et al., 2001). The result of this study indicated the limited cross-protection induced 
by inactivated IAV vaccine to heterologous challenge. This is the major problem of 
development of swine influenza vaccines. Vaccine strain mismatch with circulating strains 
may even enhance the severity of disease (Vincent et al., 2008b; Gauger et al., 2011). 
Therefore, HA antigenic match of vaccine strain and challenge strain is the key to providing 
protection by inactivated IAV vaccine. Commercial vaccines are often bivalent or trivalent, 
containing several circulating strains to increase chances of matching the challenge viruses. 
For example, Flusure XP (Pfizer, Inc., New York, NY USA) which is an IAV vaccine for 
swine use contains up to four swine influenza virus strains to provide cross protection (Lee et 
al., 2007; Pfizer Inc., 2011). However, it is difficult to cover all strains in a single dose of 
vaccine and manufacturing cost rises with increasing numbers of IAV strains in vaccines. 
Another problem of IAV vaccination is the interference of maternal antibodies in 
piglets. Anti-influenza serum IgG is transferred to piglets from maternal antibodies in sow’s 
colostrum. If sows are vaccinated with IAV vaccine before farrowing, positive IAV maternal 
antibodies (>40 fold in HI) can be detected in suckling piglets up to 14 weeks age 
(Markowska-Daniel et al., 2011). Swine influenza virus maternal antibodies are important for 
protecting young piglets and can cause of immunization failure (Wesley and Lager, 2006). 
Pigs vaccinated with commercial bivalent vaccine had better partial protection facing 
heterologous H1 challenge when maternal antibodies were absent than those possessing 
maternal antibodies (Kitikoon et al., 2006). It has been shown that the stimulation of IAV 
specific humoral responses and cellular responses in vaccinated pigs have both been 
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suppressed with the presence of maternal antibodies (Kitikoon et al., 2006). 
Mucosal responses, including IgA antibodies and cellular responses, have been the 
focus of much study to attempt to provide wider cross-protection and override maternal 
antibodies. Intranasal (IN) administration of IAV vaccines has been attempted as an 
alternative method to protect pigs and induce local immune responses (Lim et al., 2001). 
Four doses in consecutive weeks of intranasal vaccination of inactivated influenza vaccine 
provided complete protection to pigs from homologous challenge, and IgG and IgA were 
detected in mucosal secretions and serum (Lim et al., 2001). IgG induction was detected after 
the 2nd vaccination, while IgA induction was detected following the 4th vaccination (Lim et 
al., 2001). The efficacy of mucosal administration of inactivated influenza vaccine to 
override the interference of maternal antibodies in piglets needs further evaluation. Four 
doses of vaccine are not convenient for practical vaccination on pig farms, and the cost of 
four doses may not be economically feasible. It would be helpful to determine the reason(s) 
that IgG induction requires fewer doses than mucosal IgA induction by inactivated vaccine in 
order to improve intranasal vaccine development.  
Live attenuated vaccines 
Recombinant modified influenza viruses can be obtained with reverse genetics 
technology and provides a novel way to make modified live attenuated virus vaccines 
(MLV). HA0 protein, the precursor of HA, must be cleaved into HA1 and HA2 in order to 
fuse with endosomal membranes (Skehel and Wiley, 2000). HA0 modified live attenuated 
virus (∆ha0MLV) was achieved by introducing a mutation to the HA cleavage site (Stech et 
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al., 2005; Gabriel et al., 2008; Masic et al., 2010). Masic et al. (2009) showed that ∆ha0MLV 
could infect pigs without shedding live virus, proving that ∆ha0MLV is attenuated in pigs. 
The H1N1 strain of ∆ha0MLV administrated intranasally induced a significant cross 
protection to H1N1 and H3N2 challenge. Both macroscopic and histopathologic lung lesion 
scores were significantly reduced in both homologous challenge and heterologous challenge 
groups (Masic et al., 2010). Virus shedding was not detected in 5/6 pigs from homologous 
H1 strain challenge and not detected in 3/6 pigs from heterologous H3N2 challenge (Masic et 
al., 2010). Vaccinated pigs had considerable IgA in the lower respiratory tract and serum IgG 
after either homologous or heterologous challenge (Masic et al., 2010). Two dose 
vaccinations were required to induce protection for ∆ha0MLV (Masic et al., 2010).   
NS1 of swine influenza virus has been demonstrated as a virulence factor with the 
function of antagonizing type I interferon (IFN-α/β) (Talon et al., 2000). Introducing 
mutations into the gene encoding the NS1 protein causes the loss of IFN-α/β inhibiting 
potency (Talon et al. 2000; Solorzano et al., 2005). NS1 modified influenza strain 
(Sw/TX/98∆126) has been shown to be virulence attenuated in inoculated pigs by reducing 
lung lesion and live virus shedding(Solorzano et al., 2005). Induction of HI antibodies by this 
∆ns1MLV indicated it was  immunogenic (Solorzano et al., 2005). To test the efficacy of 
∆ns1MLV as an influenza vaccine candidate, pigs were vaccinated intratracheally twice with 
∆ns1MLV, followed by homologous or heterologous virus challenge. Homologous 
challenged pigs were completely protected by ∆ns1MLV and it was confirmed to be 
attenuated (Richt et al., 2006). In heterologous subtype challenge with a cH1N1 strain, 
macroscopic lung lesion scores in vaccinated pigs and unvaccinated pigs were similar, while 
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microscopic lung lesion scores and virus shedding in respiratory tract were reduced 
compared with the unvaccinated group (Richt et al., 2006).  
In another study, two doses of intranasal vaccination of ∆ns1MLV attempted to 
evaluate heterologous protection efficacy. Attenuated live influenza virus with truncated NS1 
(TX98 H3N2) was administrated intranasally (IN) by dripping vaccine into nares to evaluate 
homologous and heterologous protection. CO99 H3N2 (antigenic variant from TX98) and 
IA04 (H1N1) were the evaluated heterologous strains (Vincent et al., 2007). The results 
demonstrated that intranasal administration of ∆ns1MLV (TX98) significantly reduced rectal 
temperature, and live virus shedding and lung lesions following TX98 (cluster I) and CO99 
(cluster II) challenge (Gramer et al., 2007; Vincent et al., 2007). Modest HI antibodies 
specific to TX98, but not CO99 or IA04 were detected in serum and robust IgA and IgG 
antibodies in mucosa with cross-reactivity to CO99 were detected in IN pigs (Vincent et al., 
2007). The cross-reactive local antibodies induced by IN ∆ns1MLV vaccination indicate the 
potential of universal protection induction by intranasal vaccination. In addition, modest HI 
antibodies in serum indicate the potential to reduce IAV antibodies from sows to piglets 
through colostrum.  
Modified live attenuated virus vaccine has not been approved for usage in pigs. Cold 
adapted MLV has been approved in the US for human (FluMist) and equine (FluAvert) use 
via the intranasal route (Belshe, 2004; Paillot et al., 2006). Cold adapted MLV is achieved by 
inducing combination mutations on genes coding PB1 and PB2 proteins of IAV, which 
causes virus replication to be temperature sensitive (Solorzano et al., 2005). FluMist vaccine 
strain is not only a cold adapted virus but also a reassorted virus strain. It contains 6 segments 
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(PB1, PB2, NP, M, PA and NS) from human H2N2 (A/Ann Arbor/6/60) that contribute to 
virus attenuation and 2 segments coding HA and NA protein from circulating wild type 
influenza virus (Chan et al., 2008). 
Safety is a major concern for using attenuated live virus as a vaccine. Genome 
segments are able to reassort, there is concern that modified live vaccines will reassort with 
wild type strains in the field to produce novel virulent influenza strains. The reassortment of 
viral strain and vaccine strain require the replication of both of their genomes within a single 
cell at the same time. In all the vaccines studies above, live virus was not recovered from the 
upper respiratory tract after vaccination or in the lung. Whether there is live vaccine virus 
existing in the lung before challenge was not examined. Another concern of MLVs may 
revert to virulence over time if natural mutations occur (Babiuk et al., 2011). 
Administration route is another problem for MLV in pigs. To induce local antibodies 
in respiratory mucosa, MLV normally requires intranasal administration. Commercial 
intranasal influenza vaccine for humans or horses is administrated in the form of mist. The 
narrow space of swine nasal cavity results in low efficiency of delivering mist deeply into the 
respiratory tract. Dripping vaccine into the nose, which is only commonly performed in an 
experimental setting, is time consuming and not likely to be efficient in a commercial farm 
setting.  
DNA vaccines 
Recombinant DNAs coding IAV proteins have been evaluated as vaccine candidates 
for swine. The era of gene vaccines was started by Wolff et al. in 1990 (Wolff et al., 1990). 
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They demonstrated that protein can be expressed upon direct inoculation of plasmid DNA 
into mouse muscle (Wolff et al., 1990). The advantages of DNA vaccination are (I) one 
recombinant DNA molecule can encode multiple genes of interest, which reduces 
manufacturing cost; (II) DNA vaccines do not carry infection risks associated with MLV 
vaccines; (III) recombinant DNA can express high levels of proteins of interest in cells; (IV) 
DNA vaccines have the capacity of inducing both humoral and cellular immune responses; 
(V) there is potential for DNA vaccines to override maternal antibodies which mainly 
recognize IAV surface proteins but not genomes (Dhama et al., 2008); (VI) capacity of 
differentiating infected from vaccinated animals (DIVA), because the DNA vaccine does not 
express all the proteins of the pathogens, and will induce different immune responses than 
naturally infected animals. The barrier of developing efficacious DNA vaccine is low DNA 
transportation efficiency into target cells using a traditional intramuscular (IM) vaccination 
route (Pertmer et al., 1995; Olsen, 2000; Dhama et al., 2008).  
Gene gun delivery has been tested to enhance the efficiency of DNA transfection by 
Olsen and colleagues (2000). Two doses of gene gun administration of HA DNA vaccine to 
either pig skin or tongue resulted in high levels of HI antibodies after virus challenge; 
however, virus shedding was not completely prevented even with the co-administration of 
porcine interleukin-6 (Olsen, 2000; Larsen et al., 2001). This type of DNA vaccine 
immunization strategy may prime the pig immune system (Olsen, 2000; Larsen et al., 2001; 
Larsen and Olsen, 2002). Gene gun delivered DNA vaccine as prime and commercial 
vaccine as boost was found to reduce viral shedding similar to a two dose commercial 
vaccination strategy (Larsen et al., 2001).  
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Gorres et al. (2011) designed an IAV DNA vaccine by constructing a backbone with 
cytomegalovirus enhancer/promoter and the human T-cell leukemia virus type 1 R region 
recombined with trivalent HA genes (cH1N1, H3N2 and pH1N1) or monovalent HA gene 
(pH1N1) (Gorres et al., 2011). By three doses IM or needle-free (NF) 0.5-ml subcutaneous 
vaccination of pigs, similar levels of HI antibodies to vaccine strain virus and cellular 
immune responses were induced in both trivalent and monovalent groups with both IM and 
NF methods (Gorres et al., 2011). After H1 challenge, only IM and NF monovalent DNA 
vaccination reduced virus shedding at 3 days post challenge (dpc) and both NF trivalent and 
monovalent DNA vaccination completely protected against virus shedding at 5 dpc (Gorres 
et al., 2011). Post H3 challenge, both IM and NF Trivalent DNA vaccination reduced virus 
shedding at 3dpc and fully prevented virus shedding on 5 dpc. Minimal lung lesions were 
observed in examined vaccinated pigs (Gorres et al., 2011).  
Nanoparticles like chitosan have been tested as IAV DNA vaccine adjuvants for 
sustained release of vaccine; however low transfection efficiency of the chitosan-DNA 
vaccine is a disadvantage of this approach (Zhao et al., 2011). There remains a need for 
identification of a more efficient method to deliver DNA vaccines in order to better evaluate 
this vaccination approach. So far, high dose of DNA vaccine is required for vaccination 
which is expensive and not practical. 
Subunit IAV vaccines 
A subunit vaccine is an immunizing agent containing viral proteins, but no viral 
nucleic acid (Myers, 2010). Subunit vaccines can contain higher concentrations of specific 
proteins than inactivated vaccines (Cox and Hollister, 2009). The major components of 
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subunit swine influenza vaccine is one or several recombinant IAV proteins, the viral 
structural proteins that are not composed in subunit vaccines or the antibodies against them 
can be detected to differentiate infection from vaccinated animals. Thus subunit vaccines 
have the potential to be DIVA. IAV structural protein HA is expressed in subunit influenza 
vaccines as it is able to induce HI antibodies (Cox and Hollister, 2009; Vander Veen et al., 
2009; Shoji et al., 2011). Employing DNA recombinant technology, IAV proteins can be 
expressed in other platforms (Bachrach, 1982). Several platforms have been developed to 
express IAV subunits to replace traditional egg-based vaccine manufacturing. 
A baculovirus expression system was used to produce influenza virus HA protein in 
insect cells as a vaccine to protect against influenza infection in humans (Cox and Hollister, 
2009). Trivalent recombinant HAs, a combination of HAs derived from influenza A subtype 
H1N1, H3N2 and influenza B are comprised in a vaccine to achieve cross-protection (Cox 
and Hollister, 2009). In another method, HA, NA and M1 proteins of influenza virus 
expressed individually by baculovirus-insect platform self-assembled into high molecular-
weight enveloped influenza virus-like particles (VLPs) (Bright et al., 2007). The capacity of 
such VLPs at inducing cellular and humoral immune responses has been demonstrated in 
preclinical trials (Bright et al., 2007). Nicotiana benthamiana was also developed as subunit 
expressing platform. H5N1 HA protein formed VLPs (H5 VLP) (D'Aoust et al., 2008). 
Cross-reactive antibodies were induced in a ferret model to influenza H5 VLP and a safety 
study in humans showed no significant induction of naturally occurring serum antibodies to 
plant-specific sugar moieties (Landry et al., 2010). Both of the above platforms are now 
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employed to produce experimental influenza subunit vaccine for human use, and may be 
candidates to produce vaccines for swine use.  
An alphavirus replicon has also been employed to express IAV HA for swine 
vaccination (Vander Veen et al., 2009). There are two open reading frames (ORF) in the 
alphavirus genome (Rayner et al., 2002). All nonstructural proteins responsible for 
replicating viral RNA are encoded in the first ORF (Rayner et al., 2002). The second ORF of 
alphavirus normally encodes structural proteins which are responsible for the assembly of 
virus particles. An engineered virus genome, or replicon, containing the alphavirus ORF1 
combined with heterologous genes in ORF2 electroporated into VERO cells and is able to 
express the heterologous proteins in high levels in cultured cells (Rayner et al., 2002). IAV 
HA protein expressed by alphavirus replicon platform in VERO cells was combined with 
adjuvant and tested as an IAV vaccine for swine (Vander Veen et al., 2009). This HA subunit 
IAV vaccine was efficacious in reducing virus shedding and gross and histopathologic lung 
lesions after homologous virus challenge and induced specific HI antibodies after pigs were 
vaccinated (Vander Veen et al., 2009). These subunit vaccines are made from alphavirus 
replicon are free of the possibility of replicating virus, since no structural genes of the 
alphavirus are present (Vander Veen et al., 2009). 
Vectored vaccines 
Vectors are utilized to transport genes into cells. Vectored vaccines containing 
genomic material can express high levels of the encoded protein after cell entry. Vectors may 
be replicative or replication defective. Replication defective vectors have the ability to infect 
cells but lack essential genes for production of new virus particles. Thus, vectored vaccines 
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need two essential features. The first one is that the vectors are able to infect cells and 
transport the recombinant genome into cells. The second essential feature is that the 
recombinant genomes are able to replicate by themselves and express the gene of interest in 
high levels in infected cells. Since the gene of interest in a vector is not all the genes of the 
target pathogen, vectored vaccine can be a DIVA vaccine. A wide host range of the virus 
vector and lack of pre-existing antibodies are two other important features to be considered 
for good vector candidates. Besides transporting the vaccine gene into cells, vector particles 
are able to stimulate cellular immunity to vaccine component, providing them an advantage 
over subunit protein vaccines (Macklin et al., 1998; Rayner et al., 2002; Wesley et al., 2004). 
Because they are expressed within cells, vectored vaccine antigens have the potential to 
avoid interference from maternal antibodies. Another advantage is that a vector can express 
several different genes (Vander Veen et al., 2012).  
Human Adenovirus serotype 5 (Ad5) has been examined as an IAV vector for pigs 
(Wesley and Lager, 2006). Because the early transcription region 1 is deleted, Ad5 virus is 
replication-defective (Wesley et al., 2004). However, the recombinant gene of interest is able 
to be transcribed as it is under the control of constitutive promoters (Wesley et al., 2004). 
Pigs vaccinated with 1 dose mixture of Ad5 expressing the IAV H3N2 HA gene (Ad5 HA) 
and Ad5 expressing the H3N2 nucleoprotein (NP) gene (Ad5 NP) were completely protected 
from virus shedding and lung lesion development after homologous challenge. Pigs 
vaccinated with Ad5 HA shed low levels of virus and had low lung lesion scores which were 
not significantly different from that of Ad5 HA+Ad5 NP vaccinated pigs. Pigs vaccinated 
with Ad5 NP shed significant lower level of virus than unvaccinated pigs on 3 of 5 days after 
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challenge (Wesley et al., 2004). Furthermore, Ad5 expressing IAV H3N2 HA and NP 
proteins (Ad5-HA&NP) was shown to be able to prime the immune response in the presence 
of maternal IAV antibodies in piglets (Wesley and Lager, 2006). Piglets receiving maternal 
antibodies from gilts were administrated Ad5-HA&NP as a prime vaccine IM when suckling 
milk containing IAV maternal antibodies from gilts and boosted by commercial inactivated 
vaccine (End-FLUence 2, Intervet Inc., Millsboro, Del.) IM. Sows had antibodies to IAV 
H3N2 strain and End-FLUence 2 comprises H1N1 and H3N2 strains. Piglets were then 
challenged with a heterologous IAV H3N2 strain after boost vaccination. Better protection to 
these primed vaccinated piglets was induced compared with piglets without A5-HA&NP 
prime vaccinated pigs (Wesley and Lager, 2006). A disadvantage of Adenovirus vectors is 
the development of vector immunity (Pandey et al., 2012). Pigs can only be primed with 
adenovirus vectors, the efficacy of a boost injection will be inhibited by antibodies to the 
vector.  
Alphavirus has also been developed as a vaccine vector based on an alphavirus 
replicon. Since genes coding structural proteins of alphavirus are deleted in the alphavirus 
replicon, new alphavirus particles cannot be produced. To make vaccine alphavirus particle 
vectors, alphavirus structural protein genes as helper RNAs are transported into cells in trans 
along with the replicon during electroporation. Alphavirus-like particles, known as replicon 
particles (RP) are formed subsequently (Rayner et al., 2002).  
There are several advantages of alphavirus RP that make it an attractive vaccine 
platform candidate. Firstly, vector safety has been proven that RPs are not shed or spread to 
cohorts or into environment by vaccinated animals (Vander Veen et al., 2012b). Replication 
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deficient feature of RP was achieved by several techniques (1) dividing structural protein 
genes into two elements (Pushko et al., 1997; Smerdou and Liljestrom, 1999); (2) deleting 
26S promoters and a big portion of non-coding sequences in front of 26S including starting 
codons and stop codons in each helper elements (K.I. Kamrud, Harrisvaccines Inc., personal 
communication). Secondly, anti-alphavirus vector immunity is minimal, thus the same 
individual animals can be multiply vaccinated with RP vector based vaccines. Thirdly, a 
rapid development of new vaccine is capable with RP system (Vander Veen et al., 2012a). 
Within 6 weeks, an IAV subunit or RP can be prepared with RP system, from receiving virus 
samples (R. L. Vander Veen, Harrisvaccines Inc., personal communication). Therefore, this 
advantage of RP system offers great potential for developing autogenous IAV vaccine. In 
addition, RP vector has dendritic cell tropism, and express multivalent genes of interest 
(Vander Veen et al., 2012a). Similar as other vectors, RP based vaccine has the capacity of 
DIVA, and able to express high levels of heterologous genes. 
Venezeulan equine encephalitis virus (VEEV), a member of the alphavirus family, 
was selected as an IAV vaccine vector expressing HA protein. The VEEV has been shown to 
infect pigs, but only induces a transient viremia (Dickerman et al., 1973). Attenuated TC-83 
VEEV strain, which is a biosafety level (BL) 2 pathogen has been developed as an RP vector 
(Erdman et al., 2010). This makes manufacturing of RP based vaccine easier and safer than 
using original BL3 pathogen-3014 VEEV strain. Pigs receiving two doses of RP vaccine 
expressing HA (HA RP) produced a high level of HI antibody from 7 days post boost 
vaccination and maintained this level at least 40 days (Erdman et al., 2010). HA RP encoding 
HA gene of cluster IV H3N2 or pH1N1 protecting pigs from homologous IAV challenge in 
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two other studies confirmed the efficacy of RP vaccine (Vander Veen, 2011; Vander Veen et 
al., 2012b). In pigs vaccinated with HA RPs, live virus was not isolated from nasal swabs and 
BAL samples and lung lesions were significantly reduced, in addition to HI antibodies, cell 
mediated immunity (CMI) was stimulated by HA RP (Vander Veen et al., 2012b). Mucosal 
antibodies specific to vaccine antigen was induced by vaccine adjuvanted with alphavirus RP 
in mice model, even the vaccine administration site was not mucosa (Thompson et al., 2008). 
RP encoding homologous NP gene to challenge virus was shown to partially reduce 
virus replication in pigs and to stimulate both humoral antibodies and CMI, and the CMI 
responded to both homologous and heterologous IAV antigens in vitro (Vander Veen, 2011). 
Homologous NP RP itself did not protect pigs as well as HA RP against homologous 
challenge, NP RP along with HA RP has the potential to help piglets override maternal 
antibodies, which could be determined in a future study (Wesley and Lager, 2006; Vander 
Veen, 2011). 
Pseudorabies virus (PRV), an alpha-herpesvirus in herpesviridae, has been used as a 
vaccine vector to express IAV HA as well. PRV consists a linear double-stranded DNA 
genome with the length of 14.5 kb. Several non-essential genes exist in PRV genome, most 
of which can be deleted to reduce virulence and replaced by other genes without affecting 
virus replication (Tian et al., 2006). Based on these features, a commercial attenuated PRV 
DIVA vaccine was developed with gE deletion (Pensaert et al., 2004). In addition, the 
attenuated PRV vaccine strain (Bartha-K61) was employed as an influenza vaccine vector 
expressing HA (Tian et al., 2006; Li et al., 2010). Recombinant PRV expressing H3N2 HA 
(rPRV-HA) protected mice against homologous virus challenge (Tian et al., 2006). In rPRV-
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HA vaccinated group, live virus was not isolated from 4 dpc until the end of study from lung 
tissues and lung lesions were mild (Tian et al., 2006). Since this PRV vector is not suitable to 
be used multiple times due to immunity to the vector, prime/boost immunization with DNA 
expressing soluble HA fused with three copies murine complement C3d (HA/C3d DNA) and 
rPRV-HA was pursued (Li et al., 2010). This regimen induced better protection than one 
dose vaccination rPRV-HA in mice (Li et al., 2010). However, the protection to pigs 
provided by PRV vector influenza vaccine needs further evaluation. Attenuate PRV strain 
has good safety record and broad host range (Klupp et al., 2004; Yuan et al., 2008). These 
advantages further support PRV as an influenza vaccine vector candidate. However, 
immunity to vector limits the PRV vector use with multiple doses. Furthermore, the use of 
attenuated PRV strain as a vector may interfere with the surveillance of PRV vaccination 
(Ma and Richt, 2010). 
Vaccinia virus, composing double stranded DNA genomes, has been developed to 
another influenza vaccine vector. Modified vaccinia Ankara (MVA) is an attenuated vaccinia 
strain used widely to eradicate human smallpox (Rimmelzwaan and Sutter, 2009). The 
attenuation of MVA is created by continual passages on primary chicken embryo fibroblast 
cells (Verheust et al., 2012). The immunity induced by recombinant MVA expressing IAV 
HAs was shown to be protective in equine and mice (Breathnach et al., 2006; Kreijtz et al., 
2007). In addition, this vector can be used with the presence of pre-existing immunity in 
mice (Ramirez et al., 2000). These results indicate that MVA is competent as an influenza 
vaccine vector (Rimmelzwaan and Sutter, 2009), while whether MVAs expressing IAV 
proteins protect pigs need to be demonstrated.  
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Autogenous vaccines 
Autogenous vaccines are prepared from field virus strains, and normally are 
inactivated virus. In general, it takes 8 to 12 weeks to produce an inactivated autogenous 
vaccine (R. L. Vander Veen, Harrisvaccines Inc., personal communication). The use of 
autogenous vaccines has increased in recent years because of rapid mutation rates of IAV and 
the difficulty of vaccine manufactures in updating their vaccine strains for commercial 
availability (Vincent et al., 2008a). An estimated $16.06 million in swine autogenous 
vaccines were sold in the US from May 1999 to April 2000 (Draayer, 2004). IAV and 
porcine reproductive and respiratory syndrome disease vaccines consisted of more than half 
of the autogenous vaccines produced (Draayer, 2004). In 2006, more than 20% of all known 
IAV vaccinated breeding sows and more than 9% of IAV vaccinated nursery-age pigs were 
vaccinated with autogenous IAV vaccines (USDA, 2007). Up to 2010, around 50% of IAV 
vaccines used for swine in US market were autogenous vaccines (Ma and Richt, 2010b). 
Autogenous vaccine production is normally achieved by inactivating live virus isolated from 
an infected herd and propagating the virus (Vincent et al., 2008a). Usage of such autogenous 
vaccines is only allowed in the herd from which the vaccine virus was extracted under a 
veterinarian’s direction (Vincent et al., 2008a). Two to four different subtype viruses are 
typically contained within an autogenous vaccine mixture, but there can be up to 5 viruses. 
Efficacy of vaccine which would not be evaluated when vaccines were manufactured, but 
they may be monitored under a veterinarian’s supervision at the time of use. Recently, the 
USDA Center for Veterinary Biologics (CVB) has notified vaccine manufacturers that 
recombinant non-living vaccines may be licensed as autogenous vaccines (USDA, 2012). 
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Conclusion 
Current vaccine experiments have identified several alternative methods for safer and 
more rapid (ex. subunit vaccine, DNA vaccine or vector vaccine) vaccine production than 
traditional egg-based manufacture. Without expressing all proteins from the pathogen, these 
vaccines have the capability to be DIVA. However, most of these experimental vaccines, 
which are intended to protect infection from different influenza subtypes, has achieved 
optimal efficacy. IN MLV has nearly complete cross-protection to heterologous challenge 
and induced mucosal antibodies; however, safety is a concern and a practical IN method 
needs to be developed. As most subunit vaccine components are structural proteins of IAV, 
whether maternal antibodies will interfere with vaccine efficacy needs further evaluation. 
DNA vaccines may be an improved version of subunit vaccines as a result of high level 
expression of influenza protein(s) in hosts, although delivering DNA vaccine into cells 
erodes the efficiency of DNA vaccines. Vector vaccine may be regarded as superior to DNA 
vaccines, and is an alternative approach for DNA delivery into cells. HA protein(s) is the 
major antigenic component for induction of humoral HI antibodies through expression by 
these advanced vaccine approaches. Unfortunately, there remains the question of limited 
cross protection to heterologous challenges.  
The current method to protect against diverse influenza virus strains for commercial 
inactivated vaccine is, to include various HAs in the same inactivated vaccine dose. An 
alternative way is the use of autogenous vaccine specific to the virus strain in certain swine 
herd, which can be prepared rapidly. However, a universal IAV vaccine protecting pigs is 
still desirable.  
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Table 1 Summary of characters of different types of influenza vaccines and vaccine candidates for Swine use 
Vaccine types Features Preferred route of 
administration  Advantages Disadvantages Selected references 
Inactiv
-ated 
vaccin
-es 
Commercial  
Inactivated whole 
virus Intramuscular 
Commercial available; 
good homologous 
protection by humoral 
antibodies 
 
Limited cross-
protection;  
mismatch of strains 
enhance severity of 
disease; 
maternal antibody 
interference; 
slow manufacture  
Heinen et al., 2001; 
Kitikoon et al., 2006;  
Lim et al, 2001; 
 
Autogenous 
Specific to circulating 
strains; 
Rapid updating 
Virus source herd only; 
efficacy unknown until 
use 
Vincent et al., 2008a 
Modified live virus Live whole virus, 
reduced virulence Intranasal  
Partial cross-protection; 
mucosal antibodies 
Safety concern; 
impractical intranasal 
administration  
Masic et al., 2010; 
Richt et al., 2006; 
Solorzano et al., 2005; 
Vincent et al., 2007 
DNA  Nucleic acid only, 
without protein 
Intradermal/Subc
utaneous (gene 
gun or needleless 
injection)  
Multivalent;  
non-infective; 
CMI responses; 
potential to override 
maternal antibodies; 
DIVA 
High dose is required to 
provide sufficient 
protection 
Gorres et al., 2011; 
Larsen et al., 2001 
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Continued of Table 1. 
Subunit  Viral protein only, 
without nucleus acid Intramuscular 
Safe;  
pure target proteins; 
rapid manufacture; 
DIVA; 
possible to be available as 
autogenous vaccine 
Potential to be interfered 
by maternal antibodies 
 
Bright et al., 2007;  
Cox and Hollister, 2009; 
Vander Veen et al., 
2009 
Vector 
Vectors containing 
vaccine genes, 
expressing vaccine 
proteins; 
Vectors: Adenovirus 
Alphavirus 
Pseudorabies virus 
Vaccinia virus 
Intramuscular 
Efficient transportation of 
GOI into host cell; 
multivalent; 
CMI responses; 
safe; 
(potential to) overriding 
maternal antibodies; 
rapid manufacture; 
DIVA 
Immunity to some 
vectors; 
   
Wesley and Lager, 
2006; 
Bosworth et al., 2010; 
Erdman et al., 2010; 
Vander Veen et al., 
2011; 
Vander Veen et al., 
2012b 
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CHAPTER 3. IMMUNIZATION FOR INFLUENZA A VIRUS BY 
INTRANASAL ADMINISTRATION OF ALPHAVIRUS REPLICON 
PARTICLES  
Abstract 
An influenza A virus (IAV) vaccine that provides better cross protection to pigs 
against heterologous strain infection and overrides maternal antibodies interference is 
needed. A replicon particle (RP) platform has been developed for influenza vaccine by 
expressing hemagglutinin (HA) protein (HA RP). Prime/boost intramuscular (IM) 
administration of HA RP is able to induce protective humoral antibodies to homologous 
challenge. In this study, we evaluated the efficacy of intranasal (IN) administration with HA 
RP of pandemic H1N1 (A/CA/04/2009 H1N1) in two pig experiments. In the first 
experiment, prime/boost RP vaccination was administered IN/IN to pigs, with IM/IM 
administration as positive control and sham vaccination as negative control (five pigs each 
group). All pigs were challenged by homologous challenge following two doses vaccination. 
Pigs were not protected by IN/IN administration of RP against IAV challenge. Virus titers 
and pneumonia were not reduced significantly in RP IN/IN administered group, compared 
with control group. In the second experiment, pigs were administered with one dose HA RP 
vaccine IM or IN, or with a combination of IN/IM routes with an interval of three weeks. In 
IN/IM or one dose IM administered pigs, At most two pigs at 2 DPC and 3 DPC, and no pigs 
at 3 DPC to 5DPC were isolated with live virus. All five pigs were detected with live virus 
from one dose RP IN administered pigs and sham vaccinated pigs. We also found that one 
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dose IM and combination of IN/IM vaccination with HA RP reduced pneumonia 
significantly compared with sham vaccinated group, contrary to one dose IN vaccination. 
Introduction 
Vaccination of pigs is a common method to control IAV infection in swine. Unlike 
the human influenza seasonal epidemiology, IAV infection of swine is not seasonal and there 
are many circulating variants in North America (Vincent et al., 2008). To protect variant 
influenza strains, the current strategy of commercial inactivated vaccines is making 
multivalent vaccines. However, the number of IAV variants circulating in North America are 
too numerous for a bivalent or trivalent inactivated vaccine to comprise (Vincent et al., 
2008). Another major problem of vaccinating pigs with IAV vaccine is that maternal 
antibodies interfere with the vaccine efficacy. Therefore, an IAV vaccine, which provides 
better protection in pigs against heterologous strain infection and override maternal 
antibodies interference, is needed.  
Replication deficient Alphavirus vectored IAV vaccines were developed as 
alternative vaccine candidates. The Alphavirus genus belongs to the family Togaviridae and 
contains a positive-sense, single-stranded RNA genome of approximately 11.5 kb in length 
(Griffin, 2007). Attenuated TC-83 Venezuelan equine encephalitis virus (VEEV) strain has 
been developed as a replication deficient vaccine vector, termed as replicon particles (RP), to 
express high levels of IAV hemagglutinin (HA) genes (Erdman et al., 2010). VEEV RPs also 
have a proven safety record demonstrating that RPs do not spread into the environment or to 
control pigs (Vander Veen et al., 2012). Therefore, RP based vaccine, with this safety 
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advantage, is a good commercial vaccine candidate. RP expressing HA proteins protected 
homologous challenge and induced robust humoral immune responses administered 
intramuscularly (IM) with prime/boost strategy (Vander Veen, 2011;Vander Veen et al., 
2012).  
Intranasal (IN) administration of inactivated or modified live virus (MLV) IAV 
vaccines has been demonstrated as an alternative administration route that protects pigs and 
induces local immune responses (Lim et al., 2001). Theoretically, inducing local immune 
responses to IAV infection has a potential to override the interference of humoral maternal 
antibodies. Another alternative vaccination strategy is administering pigs only one dose 
vaccine. An Adenovirus vector expressing HA protein was found to provide protection to 
pigs with only one injection vaccination at a high dose (Wesley et al., 2004). The 
combination of adenovirus vectored IAV vaccine (prime) and commercial inactivated IAV 
vaccine (boost) have been shown to override maternal antibodies successfully (Wesley and 
Lager, 2006). Efficacy of alternative vaccination strategies of RP in protecting pigs has not 
been evaluated.  
Herein, we hypothesized that IN routes and combination of IN and IM routes of HA 
RP vaccination would protect pigs against homologous challenge, and these strategies had 
the potential to induce local antibodies and override the interference of maternal antibodies. 
In addition, we hypothesized one dose HA RP would be protective against homologous 
challenge. This study was composed of two animal experiments, the first study was to 
determine whether IN vaccination protect pigs against homologous challenge; the efficacy of 
44 
combination of IN and IM routes vaccination and one dose IM vaccination in protecting pigs 
against homologous challenge was evaluated in the second study. 
Methods and Materials 
Cells and virus 
Madin-Darby Canine Kidney (MDCK) cells were passed in minimum essential 
medium (MEM) with 5% COSMIC Calf Serum, 1% Antibiotic-Antimycotic 100X (GIBCO® 
#15240, Gand Island, NY) and 1% MEM Non-Essential Amino Acids Solution 10 mM 100X 
(NEAA) in 5% CO2 and 37 °C environment incubator. When cells were confluent in the 
flask, they were washed with phosphate buffered saline (PBS) and detached from the flask by 
trypsin 250 (Difco™ #215240, Houston, TX) incubation. Cells were split to new flasks with 
1 to 3 area ratio.   
Pandemic H1N1 (A/CA/04/2009) virus was propagated and titrated on MDCK cells 
as previously described by with modification (Szretter et al., 2006). MDCK cells were 
inoculated with 1ml pH1N1 of 105 TCID50/ml and inoculation medium [MEM medium with 
1% Antibiotic-Antimycotic 100X (GIBCO® #15240) and 2ug/ml TPCK Trypsin (Thermo 
Fisher Scientific Inc. #20233, Rockford, IL)]. Virus was filtered through a 0.45µm filter and 
stored at -80 °C before use. Virus was titrated on MDCK cells in 96 well plates by 10 fold 
serial dilution. Plates were incubated with inoculation medium in 5% CO2 and 37 °C until 
cytopathic effect (CPE) did not showed up in any more wells. Infected cells were visualized 
by IFA similar to VERO cells as previously described (Vander Veen, 2011). Virus 
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concentration was calculated by 50% Tissue Culture Infectious Dose (TCID50/ml) as 
described previously (Reed and Muench, 1938). 
Replicon particle vaccine  
Alphavirus replicon particles, expressing HA protein (HA RP) of pH1N1, was 
prepared as previously described (Kamrud et al., 2007). Briefly, HA gene cDNA was 
amplified by reverse-transcript polymerase-chain reaction (RT-PCR), using primers that 
contained EcoRV and AscI restriction sites were added into the 5’ and 3’ end of the HA 
cDNA during amplification. HA cDNA was then cloned into a replicon plasmid which 
contained non-structural protein genes of alphavirus (α-nsps) using these two restriction 
sites. This plasmid was amplified in Escherichia coli (E.coli) to a large amount. Replicon 
RNA, comprised of α-nsps/HA genes was transcribed from the plasmid in vitro and then 
purified. Helper RNAs were transcribed from helper plasmids with similar method to 
replicon. Replicon and helper RNAs were electroporated in trans into Vero cells in 
electroporation chambers. Electroporated Vero cells were incubated at 37 °C with the same 
medium as MDCK growth medium and 5% CO2 for 18 hours. HA RP was harvested from 
cell culture. Infectious unit concentration of RP was titrated on Vero cells with indirect 
immunofluorescence assay (IFA) (Kamrud et al. 2007). Goat anti-VEE NSP2 antibody was 
used as the primary antibody and Alexa Flour® 488 donkey anti-goat IgG (H+L) 
(Invitrogen™ #A11055, Grand Island, NY) was used as the secondary antibody. Vero cells 
infected with RP were observed microscopically at 488nm wave length filter.  
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Animal studies 
Experiment 1 
Three week old commercial pigs were used in this study. Fifteen pigs were confirmed 
negative for IAV and porcine reproductive and respiratory syndrome virus (PRRSV) 
antibodies by commercial ELISAs against IAV NP protein (IDEXX AI multiS-Screen Ab 
Test by IDEXX Laboratories, Westbrook, ME) and PRRSV NP protein (HerdChek X3 by 
IDEXX Laboratories, Westbrook, ME). ELISA assays were performed by Iowa State 
University Veterinary Diagnostic Laboratory (ISU VDL). Pigs were randomly sorted by 
weight into three groups with five pigs per group and assigned to three separated rooms at 
arrival. Ceftiofur per labeled dose antibiotic (Excede® for swine by Pfizer Animal Health, 
New York, NY) was injected intramuscularly to prevent bacterial infection. At four week of 
age (day 0), Control pigs received 2ml PBS intra-nasally as placebo, while the other two 
groups were administered 2ml pH1N1 HA RP containing 108 IU RP intra-nasally (IN/IN 
group) with an aerosolization instrument (Pump It by Genesis Instruments Inc., Elmwood, 
WI) or intramuscularly (IM/IM group) (Table 1). On day 21, pigs were administered the 
same vaccine or placebo according to their group as a booster vaccination. On day 42, all 
pigs were challenged intratracheally with 10 ml IAV pH1N1 strain virus at a dose of 104 
TCID50/ml. On day 47, all pigs were euthanized and necropsied. Pigs were sedated with IM 
Telazol® (100mg/ml, Fort Dodge Animal Health, Fort Dodge, IA) at a dosage of 1ml per 100 
pounds IM. Beuthaniasia-D (Schering-Plough Animal Health, Union, NJ) with a dosage of 
1ml per 10 pounds given intravenously (IV) was used for euthanasia. The Institutional 
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Animal Care and Use Committee (IACUC) at Iowa State University approved this animal 
study. 
Experiment 2 
Twenty-five, three week old commercial weaned pigs were randomized by weight 
into five groups with five pigs in each group upon arrival and assigned to one of five rooms 
isolated from each other. Serum samples were collected and evaluated by commercial 
ELISAs against influenza A NP protein (IDEXX AI multiS-Screen Ab Test by IDEXX 
Laboratories) and PRRSV NP protein (HerdChek X3 by IDEXX Laboratories). ELISA 
confirmed that all serum samples were negative of SIV and PRRSV antibodies. Antibiotic 
per label dose was injected intramuscularly. The pigs were then treated with different 
vaccination protocols as outlined in Table 2. The (IM)/(IM) group served as negative 
vaccination control. All HA RP doses were 108 IU in 2ml. All pigs were challenged 
intratracheally with pH1N1 strain of IAV at dose of 104 TCID50/ml by10 ml on day 42. On 
day 47, all pigs were euthanized and necropsied as experiment 1. This animal study was 
approved by the Institutional Animal Care and Use Committee (IACUC) at Iowa State 
University. 
Sample collection 
For both experiments, blood samples were collected before prime vaccination (day 0) 
and once a week after day 0, before challenge (day 42), and at necropsy (day 47). Nasal 
swabs were collected daily from day 41 until necropsy. Nasal swab samples were kept in 
1.5ml MEM medium with 2% Antibiotic-Antimycotic. Bronchoalvoelar lavage (BAL) 
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samples were collected during necropsy. All blood, nasal swab and BAL samples were 
transported in ice and stored at -80 °C until use.  At necropsy, lungs were removed and tissue 
samples from each lobe and trachea were collected and fixed in 10% formalin. 
Clinical observation 
Coughing, respiratory rate and behavior, were observed daily from one day prior 
challenge. Coughing was scored between 1 and 4 to reflect the severity according to the 
following criteria: 1= none; 2= soft or mild intermittent cough; 3= harsh or severe, repetitive 
cough; 4= dead. Respiration were scored between 1 and 4 to reflect respiratory syndrome 
severity according to the following criteria: 1= normal; 2= panting/rapid; 3= dyspnea; 4= 
dead. Behavior was assigned a score between 1 and 4 according to the following criteria: 1= 
normal; 2= mild lethargy; 3= severe lethargy or recumbancy; 4= dead. Coughing score, 
respiration score and behavior score of each pig on every observed day were summed up as a 
clinical score. Body temperatures were determined twice a day from sub-dermal chips in the 
morning and evening from one day prior challenge until the end of animal study. Electronic 
temperature measuring chips (LifeChip® by Destron Fearing™, South St. Paul, MN) were 
injected intramuscularly into pigs’ necks. Pigs’ body temperatures could be received by 
Bluetooth scanner, when the scanner was close to pig’s neck. Weight was determined at 
arrival, before challenge and at necropsy. Daily weight gain (Lb) after challenge was 
calculated.  
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Live virus isolation 
Live virus titers were determined with medium containing nasal swab samples and 
BAL samples as previously described with modification (Vincent et al. 2010). When MDCK 
cells were at monolayer on 96-well cell culture plates, supernatant was removed from the 
plates. Medium submerging nasal swab and BAL were thawed and centrifuged to discard 
cellular debris. Supernatant were diluted 10-fold from 10-1 to 10-7 in another 96-plate. 
Diluent was MEM medium containing 1% Antibiotic-Antimycotic (GIBCO® #15240) and 
0.2mg/ml TPCK trypsin (Thermo Fisher Scientific Inc. #20233). Diluted samples (100 µl) 
from each well were transferred to MDCK plates. MDCK plates were incubated in 37 °C 
with 5% CO2 for 3-5 days until no CPE showed up in any more wells. Titers were calculated 
as TCID50/ml as virus isolation protocol. 
Hemaglutination inhibition assay 
Antibodies in pig sera against influenza HA protein, were measured by HI assay 
performed by ISU VDL following standard laboratory protocol. Briefly, serum samples from 
pigs were treated with receptor-destroying enzyme overnight to remove nonspecific 
hemagglutinin inhibitors in serum. Complements in serum samples were heat inactivated. 
The serum samples were absorbed with 20% turkey erythrocytes and centrifuged. 
Supernatants were serially diluted in u-shaped bottom well microtiter plates with an equal 
volume containing 4-8 agglutinating units of pH1N1 strain and plates were incubated at room 
temperature before addition of 0.5% turkey erythrocytes. Titer was defined as reciprocal of 
the maximal dilution that inhibited hemagglutination.  
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Pathology  
The severity of pneumonia was determined by macro-pathological lung lesion scores 
and histopathological [hematoxylin and eosin (HE) and immunohistochemistry (IHC)] 
scores. Gross lung lesions were observed and assigned to a score from 0 to 100 based on 
weighted proportions reflecting the estimated total percentage of lesions to whole lung 
volume (Halbur et al., 1995). Fixed tissues were sent to ISU VDL for HE staining and 
Influenza virus A specific IHC staining (Vincent et al., 1996). HE stained samples were 
scored 0 to 3 reflecting the severity of bronchial epithelial injury (Richt et al., 2003; Vincent 
et al., 2007). IHC stained samples were scored 0 to 3 depending on amount of influenza virus 
antibody stained cells with the following criteria: 0= no staining; 1= mild staining; 2= 
moderate staining; 3= marked staining. All scoring work was done by a board-certified 
veterinary pathologist who was blind to pig treatment. 
Statistical analysis 
 Single factor analysis of variance (ANOVA) was used to analyze temperatures, 
average daily gain of weights, gross lung lesion scores, histopathological lung lesion scores, 
log 10 transformed nasal swab and BAL viral titers. Statistical significance was set at two 
sides p<0.05. 
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Results 
Experiment 1 
Clinical evaluation 
After challenge, clinical signs of influenza observed in this study were mild even in 
the sham vaccinated group. At most, two coughing pigs were observed in each group every 
day. No respiratory syndrome or lethargy was observed in any group after challenge until the 
end of study. Daily weight gain of sham group was 1.5±0.2, IN/IN group was 1.9±0.2 and 
IM/IM group was 1.4±0.2. The means of clinical scores of each day, means of body 
temperatures of each observation and means of AGD post challenge of IN/IN group and 
IM/IM group are compared with sham group, and no significant differences were observed. 
Live virus isolation 
Average titers of live virus isolation from nasal swab and BAL samples within each 
group, are summarized in Figure 1A. The number of pigs from which live virus was isolated 
were indicated as well. No live virus shedding was detected in IM/IM group post challenge in 
nasal swab samples or BAL samples. Live virus shedding was detected in nasal swab 
samples of both sham group and IN/IN group from 2 DPC until day of necropsy and in BAL 
samples. Means of virus titers of both groups were not significantly different. Means of virus 
titers from nasal swab samples peaked and all samples were isolated with live virus on 4 
DPC in both groups. However, there were fewer pigs isolated with virus in IN/IN group than 
the sham group from nasal samples on 3 DPC (3 pigs in sham group 1 pig in IN/IN group) 
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and 5 DPC (4 pigs in sham group and 2 pigs in IN/IN group) and from BAL samples on 
5DPC (4 pigs in sham group and 1 pig in IN/IN group).  
Hemagglutin inhibition assay 
HI assays to the challenge virus strain were performed and the Geometrical group 
means of HI titers are summarized in Figure 1B. On the day of boosting vaccination (day 21), 
mean of IM/IM group HI titers was 20, and was un-measurable in IN/IN group or sham 
group. Eight days later, mean of HI titers in IM/IM group increased to 140 and remained 
above this titer until the end of study, with the highest mean (243) on day 35. IN/IN group 
did not have a detectable HI titer before challenge (day 42) and HI antibodies with mean titer 
of 23 were detected after challenge (day 45). No detectable HI antibodies appeared in the 
sham vaccinated group throughout the study.   
Macro-pathological and histopathological evaluation 
Macro-pathological lung lesions, associated with influenza virus, were prominent in 
the sham vaccinated group. Macro-pathological lesions, including red consolidation mainly 
on cranioventral lung lobes, were observed in all pigs in sham (16.6±3.0) and IN/IN group 
(14±3.4) and two pigs in IM/IM group (1.6±1.0; Figure 2A). Necrosis of bronchial epithelial 
cells, inflammation around bronchia and neutrophil aggregation were observed on all HE 
stained specimens of sham (1.7±0.1) and IN/IN (1.8±0.3) groups and one of IM/IM group 
(0.2±0.2; Figure 2B). Influenza A, stained by IHC and showing brown color, was observed in 
bronchia epithelial cells in all sham (2±0.5) and IN/IN (1.4±0.2) groups samples, while was 
not observed in IM/IM group (Figure 2C). Mean macro-pathological scores and mean 
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histopathological scores (HE and IHC) of IM/IM group were significantly lower than the 
sham and IN/IN groups (Figure 2A,B&C). However, sham and IN/ IN groups did not have 
significant differences neither in macro-pathological scores, nor in histopathological scores.  
Experiment 2 
Clinical evaluation 
Panting, rapid breathing and dyspnea, were observed post challenge in all groups, but 
these syndromes appeared prior to challenge. Behavior and appetite were normal post 
challenge in all groups. No lethargy was observed in any group. Means of clinical scores had 
no significant differences among all groups on any observed day. Compared with (IM)/(IM) 
group, a significantly higher mean body temperature was observed in IM/IM group at 36 
hours prior challenge and significantly lower in IN/IM group at 60 hours post challenge. 
Other than these two significant differences, mean body temperatures for each group were 
not significantly different from (IM)/(IM) group. For Daily weight gain post challenge, 
IN/IM group (0.5±0.1) was significant lower than all the other groups. The other four groups, 
(IM)/(IM) group (1.2±0.1), IN/(IM) group (1.1±0.2), (IN)/IM group (1±0.3) and IM/IM 
group (1.2±0.1), had no significant difference. 
Virus isolation 
Virus shedding was completely eliminated from nasal swab or BAL samples in 
IM/IM group (Figure 3A). Live virus was detected in all pigs of IN/(IM) group and 
(IM)/(IM) group from nasal swab samples from 3 DPC to day of necropsy. BAL samples 
from three pigs in IN/(IM) group and four pigs in (IM)/(IM) group were detected with virus. 
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In IN/IM group and (IN)/IM group, live virus has been isolated at 2DPC and 3DPC, from at 
most two pigs from each group. Mean virus titers were both significantly lower than that of 
(IM)/(IM) group at 3DPC. Virus was cleared in these two groups from 4 DPC in nasal swab 
or BAL samples. There was no significant difference in virus titers detected between these 
two groups.  
Hemagglutinin inhibition assay  
After prime vaccination (day 0) in IM/IM group, there was less than 20-fold increase 
in group mean of HI antibodies, which lasted until the boost vaccination (day 21, Figure 3B). 
HI mean antibody titer increased to 139 (range from 80 to 320) after boost vaccination in 
IM/IM group and remained at least 80 until the end of the study. HI levels were not raised 
post challenge in IM/IM group. HI antibody titers of IN/IM group and (IN)/IM group showed 
a similar trend and there was no detectable HI antibody induced until two weeks post boost 
vaccination (day 35). On day 35, HI antibodies, of about 20-fold increase (range from 15 to 
23), were detected and lasted until challenge in these two groups. Post challenge, HI 
antibodies increased to 70-fold (40 to 160) in both these groups. In IN/(IM) group and 
(IM)/(IM) group, no detectable HI antibodies were observed through out the study.  
Macro-pathological and histopathological evaluation 
Severe macro-pathological and histopathological lung lesions were observed in 
IN/(IM) group and (IM)/(IM) group. In acutely infected cells, influenza viruses stained by 
IHC were observed. In later infection, inflammatory cells gathered in the airway under 
epithelial cells and some epithelial cells were degenerated and neutrophils migrated in to the 
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airway. Pneumonia of IN/(IM) group was reduced when compared with (IM)/(IM) group, but 
this reduction was not significant (Figure 4 A,B&C). Pneumonia of the IM/IM group, IN/IM 
group and (IN)/IM group was significantly reduced compared with (IM)/(IM) group (Figure 
4 A,B&C).  
Discussion 
In both experiments, two doses of IM vaccination induced a high level of HI 
antibodies post boost, completely eliminated homologous virus propagation in lung and nasal 
cavity, and significantly reduced lung lesions. These results confirm the efficacy of RP 
expressing pH1N1 HA protein as demonstrated in previous studies (Vander Veen, 2011).  
Virus replication was partially inhibited by two doses of IN vaccination with HA RP. 
However, Virus titers of the IN/IN group were not reduced significantly when compared with 
the control group on any day, even fewer pigs had live virus isolated from nasal cavity on 
3DPC and 5DPC and from lung on 5DPC. The shortened period of virus shedding did not 
limit the severity of pneumonia, however, it has the potential to limit virus spread within the 
herd and accelerate recovery from pneumonia. One dose IN vaccination did not prevent virus 
shedding by titer or pig numbers, pneumonia, nor prime humoral immune responses.  
There were no detectable HI antibodies found in IN/IN group prior to challenge. 
Since the vaccine was administered to a mucosal site, the vaccine may not induce strong 
systemic immune responses. In contrast to the control group, there were low levels of HI 
antibodies induced in IN/IN group post challenge. This result agreed with a previous study, 
where pigs were protected by IN MLV, modest HI antibodies were induced in vaccinated 
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pigs, while local IgG and IgA levels in lung were significantly higher than that of 
unvaccinated pigs (Vincent et al., 2007). Compared with IM/IM administration, IN/IN 
administered HA RP did not provide protection to pigs against IAV challenge. A possible 
reason may be due to the inefficient administering instrument. The quantitative aerosolization 
instrument used in this study provided a fast and easy way to administer the vaccine intra-
nasally. However, the vaccine droplets, that may not deeply penetrate the pigs’ upper 
respiratory tract, may be sneezed out easily preventing vaccine adherence to respiratory 
epithelial cells. It is additionally possible that the numbers of RP infected cells was not 
sufficient to induce protective immune responses in this study.  
Prior to challenge, HI titer in (IN)/IM group was about 20 fold, which was relatively 
low compared with IM/IM group. Three pigs in the (IN)/IM group were completely protected 
from virus shedding post challenge (data not shown). For pigs shedding virus in (IN)/IM 
group, the shedding was stopped faster than (IM)/(IM) group. This indicated that a low titer 
(lower than 20 fold) of HI antibodies could protect pigs facing influenza infection. In another 
study, when pigs were challenged with IAV, virus shedding was cleared at 7 days post 
challenge, while HI antibodies did not rise dramatically until 14 days post challenge (Larsen 
et al., 2000). This indicated that the clearance of virus may not require a high level of HI 
antibodies, which supported the result of current study. With the presence of such low level 
of HI antibodies circulating in serum, HI titer rose rapidly (in 7 days) after boost vaccination 
or after virus challenge, which resulted in the reduction of infection (Figure 4). Gross lung 
lesions in IM/IM, IN/IM and (IN)/IM groups were reduced significantly compared with 
(IM)/(IM) and IN/(IM) groups. No significant difference was found among IM/IM, IN/IM 
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and (IN)/IM groups. Therefore, the importance of low level of HI (<40 fold) was highlighted 
and one dose IM vaccination with RP was efficient to protect against influenza in pigs.  
IN/IM vaccination protected against macro-pneumonia and micro-pneumonia better 
than (IN)/IM vaccination, although the differences were not statistically significant. Also, 
IN/IM vaccination partially protected against virus shedding and cleared up virus shedding as 
fast as (IN)/IM vaccination. This demonstrates protection induced by IN/IM administering 
HA RP against homologous challenge. Whether IN/IM vaccination provides better cross 
protection or is able to avoid interference by maternal antibodies is worth to be evaluated in 
future studies.  
The challenge virus was delivered intratracheally, at a site lower than intra-nasal 
vaccination site. Whether the challenge site was protected by local antibodies induced by 
vaccine may be a concern. However, this should not be a factor that affects intranasal 
vaccination efficacy. MLV administered both intra-nasally or intratracheally protected 
homologous intratracheal virus challenge (Richt et al., 2006; Vincent et al., 2007).  
There were pleurisies and fibrinouspleurisy in lungs observed in several pigs, which 
indicated chronic bacterial infection, and pigs showed clinical respiratory syndromes prior to 
challenge occasionally in experiment 2. This chronic pre-infection may have confused 
clinical syndromes caused by influenza infection post challenge. In addition, this might also 
affect pig growth. Three pigs in IN/IM group showed clinical syndromes prior to challenge. 
Growth of IN/IM group was significant slower than IN/(IM) group, IM/IM group and 
(IM)/(IM) group. The chronic pre-infection might contribute to the slower grown rate in 
IN/IM group. On the other hand, the 5 days period may not be long enough to show a 
58 
statistically significant difference in weight gain, and further, the sample size limited 
statistical analysis. 
In conclusion, two doses of IM vaccination of pH1N1 HA RP protected against virus 
shedding completely and reduced pneumonia significantly in homologous challenge; two 
doses IN administration of HA RP did not protect pigs against IAV; one dose IM and 
combination IN/IM routes vaccination with HA RP reduced pneumonia significantly and 
partially inhibited virus shedding following homologous challenge.  
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Table 2. Experiment 1: Study protocol.  
Group name Pig 
numbers 
Day 0 prime 
vaccination 
Day 21 boost 
vaccination 
Day 42 
challenge 
Day 47 
necropsy 
pigs 
Sham 5 IM PBS IM PBS pH1N1 IAV2 5 
IN/IN 5 IN RP1 IN RP pH1N1 IAV 5 
IM/IM 5 IM RP IM RP pH1N1 IAV 5 
1: RP expressing HA protein of pandemic H1N1 subtype. 2: All challenged virus was in a 
dose of 104 TCID50/ml in 10ml. 
 
Table 2. Experiment 2: Treatment protocol.  
Group name Pig 
numbers 
Day 0 prime 
vaccination 
Day 21 boost 
vaccination 
Day 42 
challenge 
Day 47 
necropsy 
pigs 
IN/(IM) 5 IN RP1 IM placebo pH1N1 IAV2 5 
IM/IM 5 IM RP IM RP pH1N1 IAV 5 
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(IM)/(IM) 5 IM placebo IM placebo pH1N1 IAV 5 
1
 RP expressing HA protein of pandemic H1N1 subtype. 2 All challenged virus was in a dose 
of 104 TCID50/ml in 10ml. 
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with standard error bars, statistic analysis was 
aracters, numbers in brackets are the number of 
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CHAPTER 4. ALPHAVIRUS REPLICON PARTICLES OF DELTA1 
SUBTYPE OF INFLUENZA A VIRUS: VACCINE DOSE 
DETERMINATION, HEMAGGLUTININ INHIBITION AND 
CHALLENGE RESPONSES 
Abstract 
Alphavirus recplicon particle (RP) is a replication deficient virus vector expressing 
genes of interest. RP expressing influenza virus hemagglutinnin (HA) proteins have been 
developed as an influenza A virus (IAV) vaccine candidate for swine use. HA RP monomers 
of delta1 H1N2 cluster and H3N2 strains were administered to pigs intramuscularly by a 
prime/boost vaccination respectively. The immunogenicity of these RPs at varying doses 
[1×107 (infectious unit) IU to 5×105 IU], was evaluated in this study. Two H3N2 RP 
vaccinated groups with 106 IU or 5×105 IU RP as negative control, and two delta1 RP 
vaccinated groups with 106 IU or 5×105 IU RP were all challenged with delta1 IAV virus 
homologous to delta1 RP. RPs at 5×105 IU or higher doses tested in this study were sufficient 
to induce hemagglutinnin inhibition (HI) detectable antibodies. HI titers were greater at 
increasing vaccine doses. Delta1 RP 106 IU or 5×105 IU doses, which induced HI antibodies 
with mean titers equal or lower than 20, partially prevent homologous infection by 
eliminating virus replication in lung on day 5 post challenge. However, compared with H3N2 
RP vaccinated pigs, decreased lung lesions observed in delta1 RP vaccinated pigs were not 
statistically significant.    
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Introduction 
Reassortment of H3N2 subtype with hemagglutinin (HA) and neuraminidase (NA) 
from human influenza A virus (IAV) lineages H1N1 and H1N2 subtypes forming huH1N1 
(δ2 or delta2) and huH1N2 (δ1 or delta1) have been reported as spreading in US swine herds 
(Vincent et al., 2009; Lorusso et al., 2011). According to data from the University of 
Minnesota Veterinary Diagnostic Laboratory, of all IAV received isolates from swine in 
2010, 18% were huH1N2 and 9% were huH1N1 (Pfizer Inc., 2012). Serologically, there is 
moderate to good HA antibody-antigen cross-reactivity between classical H1 and reassortant 
H1cluster β and H1cluster γ, but limited cross-reactivity among cluster β, γ and δ, or 
within δ cluster (Vincent et al., 2008a; Lorusso et al., 2011). 
Vaccination is an effective way to control IAV infection to pigs. Traditional 
inactivated IAV vaccine has been the only commercially available vaccine for swine use for 
almost 20 years (Platt et al., 2011). Limited cross protection is the major obstacle of 
controlling IAV by vaccination strategies (Vincent et al., 2010). The most widely used 
strategy to prevent newly emergent IAV strains is the adding of new strains into vaccines. 
However, mismatch of inactivated monovalent vaccine strains with challenge virus strains 
may enhance disease severity including pneumonia and clinical syndromes (Vincent et al., 
2008b; Gauger et al., 2011). Autogenous inactivated vaccines have been used in increasing 
numbers of swine herds (Draayer, 2004; USDA, 2007; Ma and Richt, 2010) . The 
development of autogenous vaccines normally takes three months to manufacture a vaccine 
specific to the prevalent strain in a herd, and this method is much more rapid than updating 
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commercial inactivated vaccine (R. L. Vander Veen, Harrisvaccines Inc., personal 
communication).  
The Alphavirus recplicon particle (RP) system consists of a replication deficient 
vector expressing a gene of interest with high efficiency and has been employed to develop 
IAV vaccines (Erdman et al., 2010). An IAV RP vaccine can be produced within six weeks 
of receiving virus samples or sequences, (R. L. Vander Veen, Harrisvaccines Inc., personal 
communication). Such rapid speed compared with inactivated autogenous vaccines is a big 
advantage of RP based vaccines. In addition, because they only express the HA proteins of 
IAV, RP vaccines only induce antibodies against HA qualifying these vaccines as a 
Differentiating Infected from Vaccinated Animals (DIVA) vaccine (Vander Veen et al., 
2012a). Since RPs are replication deficient, vaccine safety is not a concern. There have been 
no indications of vaccine spreading to the environment or to un-vaccinated pigs in previously 
published studies (Vander Veen et al., 2012a). RPs expressing HA of pandemic H1N1 
subtype (pH1N1 RP) or cluster IV H3N2 subtype (H3N2 RP) were shown to protect against 
homologous challenge by significantly reducing virus shedding and lung lesions (Vander 
Veen, 2011;Vander Veen et al., 2012b). Thus, all above features support RP based vaccines 
as autogenous vaccine candidates.  
An RP expressing HA of delta1 subtype (delta1 RP) was developed recently. In this 
study, the immunogenicity of delta1 RP and H3N2 RP at lower doses than previously 
evaluated were determined (Vander Veen, 2011; Vander Veen et al., 2012b) along with the 
efficacy of delta1 RP protecting pigs against homologous challenge.  
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Methods and Material 
Replicon particle vaccines and influenza virus preparation 
RP expressing influenza virus HA proteins were produced as described previously 
(Vander Veen, 2011). Briefly, HA genes of a cluster IV H3N2 subtype isolate (H3N2) and a 
cluster delta1 subtype strain of influenza virus were sequenced, amplified with PCR and 
cloned into a plasmid with using restriction enzyme sites that were incorporated into the PCR 
oligonucleotide primers. The plasmid also encodes DNA sequences of non-structural proteins 
of the alphavirus TC-83 strain. HA genes were inserted downstream of an alphavirus 26S 
promoter (Kamrud et al., 2007). The plasmid was transfected into Escherichia coli (E.coli) 
and amplified. Purified plasmid was linearized and transcribed into RNA to create the 
replicon. Replicon RNA and helper RNAs were electroporated into VERO cells. Eighteen 
hours later, RPs were harvested from VERO cells and purified with sucrose (Kamrud et al., 
2007). RP concentration was titrated on VERO cells as described following. Indirect 
immunofluorescent assay (IFA) was performed on VERO cells inoculated with RPs to 
visualize infected cells. Infectious units (IU) were determined by observed numbers of 
infected cells. Individual RPs were diluted to specific concentration with diluent composed 
of 60% sucrose, 1% normal swine serum (NSS) and 39% phosphate buffered saline (PBS).  
An influenza virus delta1 strain homologous to the strain used to design delta1 RPs, 
was propagated on MDCK cells and purified, then stored as stock solutions at -80 °C 
(Szretter et al., 2006). Confluent MDCK cells in T175 flasks were inoculated with 1 ml 105 
TCID50/ml Delta1virus and minimum essential medium (MEM) complemented with 1% 
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Antibiotic-Antimycotic 100X (GIBCO® #15240, Gand Island, NY) and 2ug/ml TPCK 
Trypsin (Thermo Fisher Scientific Inc. #20233, Rockford, IL). When all cells detached from 
the flasks, the flasks were frozen at -80°C and thawed to lyse MDCK cells. Medium with 
virus and cell lysate was centrifuged at 4000 rotations per minute (rpm) for 45 minutes at 
4°C. The supernatant was purified through a 0.45µm filter. The filterate was titrated on 
MDCK cells and used as the challenge virus.  
Animal studies 
Thirty-five three week old piglets were purchased from a commercial sow farm. 
Upon arrival, pigs were weighed and randomly assigned to 7 groups with 5 pigs per group 
blocked by weight (Table 1). Ceftiofur (Excede® for swine by Pfizer Animal Health, New 
York, NY) was injected into all pigs per labeled dose of to prevent bacterial infection. Serum 
samples were collected and evaluated by commercial ELISAs for influenza A NP protein 
(IDEXX AI multiS-Screen Ab Test by IDEXX Laboratories, Westbrook, ME) and porcine 
reproductive and respiratory syndrome virus (PRRSV) NP protein (HerdChek X3 by IDEXX 
Laboratories, Westbrook, ME). After one-week of acclimatization, all pigs began a series of 
2 ml intramuscular (IM) prime/boost (day 0/day 21) vaccinations three week apart. Each 
group was vaccinated with different RPs of varying doses. On day 42, H3-e6, H3-5e5, δ1-e6, 
and δ1-5e5 groups were challenged intratracheally with 10 ml of 104 TCID50/ml delta1 strain 
influenza virus homologous to delta1 RP source virus. H3 RP vaccinated groups served as 
challenge control in post challenge study and pigs in all the other groups were euthanized on 
day 42. Serum samples were collected weekly from day of boost vaccination (day 21) to day 
of challenge (day 42) or/and during necropsy (day 45). Rectal temperatures were measured 
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and clinical observation scores were assigned to challenged pigs daily from day 42 until 
necropsy (day 45). One pig in δ1-5e5 group died prior to challenge. Challenged pigs were 
euthanized at 5 days post challenge (dpc) and necropsied. Macro-pathological lung lesions 
were observed and scored (0 to 100) blindly by a board-certificated pathologist based on 
weighted proportions reflecting the estimated total percentage of gross lung lesions to whole 
lung volume (Halbur et al., 1995). Bronchoalveolar Lavage (BAL) samples and lung tissue 
samples were collected from each lobe.  
Replicon particle titration and indirect immunofluorescence assay 
To titrate RPs, VERO cells were seeded on 48 well plates and incubated overnight at 
37 °C and 5% CO2. Tenfold serial dilutions were made to RPs with MDCK grown medium 
as diluent. Confluent VERO cells were inoculated with the serial dilutions of RP and 
incubated for 24 hours. VERO cells were fixed by ice-cold acetone/methanol (1:1) for 5-8 
minutes followed by three washes with Imidazole Buffered Saline with Tween 20 (KPL # 50-
63-00, Gaithersburg, MD). Goat antibodies specific to the NSP protein of Venezuela equine 
encephalitis virus, was diluted by 1:200 with COSMIC Calf Serum (CCS)/PBS (1:1) and 
were coated on MDCK cells for 1 hour at 37 °C. Alexa Flour® 488 donkey anti-goat IgG 
(H+L) (Invitrogen™ #A11055, Grand Island, NY) antibodies were then incubated on cells 
after three washes. After one hour of incubation at 37 °C followed by three more washes, 
infected cells were counted using an inverted fluorescent microscope equipped with a 488nm 
wave length filter to determine infectious unit (IU) of RP. 
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Clinical evaluation 
Clinical signs, correlated to influenza infection and rectal temperatures, were 
evaluated daily starting on the day of challenge (day 42) until necropsy (day 45). Coughing, 
respiratory rate, and behavior were assigned the following scores. Coughing scoring was: 
1=none, 2=soft or mild intermittent cough, 3=harsh or severe, repetitive cough, 4=dead. 
Respiratory scoring was: 1=normal, 2=panting/rapid, 3=dyspnea, 4=dead. Behavior scoring 
was: 1=normal, 2=mild lethargy, 3=severe lethargy or recumbancy, 4=dead. Behavior score, 
coughing score, and respiratory score were summed up as a clinical score of each pig on each 
day.  
Live virus isolation 
BAL samples in MEM with 1% Antibiotic-Antimycotic, were stored at -80 °C until 
use. Medium was centrifuged at 3500 rpm for 25 minutes and the supernatant was collected 
for virus isolation. Virus isolation protocol was similar to RP titration. MDCK cells seeded 
on 96 well plates were inoculated by influenza virus along with 2µg/ml TPCK trypsin 
(Thermo Fisher Scientific Inc. #20233) and incubated for 5 days until no more cytopathic 
effect (CPE) emerged. IFA was performed with 1:1000 dilution of mouse anti-NP protein of 
influenza A (EMD Millipore Corporation #MAB8257, Billerica, MA) followed by 1:1000 
dilution of Alex Fluor® 488-conjugated donkey anti-mouse IgG (H&L) antibodies 
(Invitrogen™ #A21202, Grand Island, NY). The Reed-Muench equation was used to 
determine virus titers (Reed and Muench, 1938). 
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Hemagglutin inhibition assay 
Serum samples were sent to University of Minnesota veterinary diagnostic laboratory 
(UM VDL) to perform hemagglutinin inhibition (HI) assay. The HI assay protocol was 
similar to one previously described (Vander Veen et al., 2009). Homologous HA antigens 
matched to different RPs, were used in the HI assay. The titers of HI antibodies induced by 
delta1 RP against a heterologous strain in the same cluster and a heterologous cluster delta2- 
Pfizer XP 31 strain, were also evaluated. Titers of HI antibodies in serum against specific HA 
proteins were determined based on two fold dilutions with a minimum detectable titer of 10.  
Pathological evaluation 
Lung tissue samples were placed into 10% formalin. Twenty-four hours later, 
processed samples were transferred to 70% ethanol and stored at room temperature until sent 
to Iowa State University Veterinary Diagnostic Laboratory (ISU VDL).  Hematoxylin and 
eosin (HE) staining and influenza virus A specific immunohistochemistry (IHC) staining 
were performed on each sample (Vincent et al., 1996). HE stained samples were scored 0 to 
3 reflecting the severity of bronchial epithelial injury according to the method by Vincent et 
al. (Vincent et al., 2007). IHC stained samples were scored 0 to 3 depending on amount of 
influenza virus antibody stained cells using following criteria: 0= no staining, 1= mild 
staining, 2= moderate staining, 3= marked staining. A board-certified veterinary pathologist 
did all scoring work blind to pig treatment. 
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Statistics 
Single factor analysis of variance (ANOVA) was used to evaluate the significant 
difference of data. P-value of statistic significant difference was <0.05 two sided. Linear 
regression was used to evaluate the relationship of HI titers and different doses. Linear 
regression between delta1 RP doses (x) and transferred HI titers against homologous strain 
(y) was tested. Original HI titers (z) were transferred as following: y=log2(2z/10).  
Results 
Clinical evaluation 
The behavior of all challenged pigs was normal; pigs were aware, active and not 
lethargic. Mild respiratory syndromes, correlated to influenza, were observed, including mild 
coughing, panting, and rapid breathing. Means of clinical scores for each group on each 
observed day were not significantly different among groups (range from 3±0 to 3.4±0.2). 
Most pigs were not observed with pyrexia with the highest temperature (105 °F) only 
observed at 1 time-point in one pig. At all time-points, the means of body temperatures were 
not significantly different among all groups.   
Live virus isolation 
No virus was isolated from BAL samples of δ1-e6 and δ1-5e5 groups (Figure 1). All 
pigs that received H3 RP had detectable levels of live virus in BAL samples. Mean virus 
titers in H3 RP vaccinated groups with 1×106 IU RP (4±0.2) and 5×105 IU RP (4.5±0.4) were 
not significantly different.   
74 
Hemagglutinin inhibition assay 
In H3N2 RP vaccinated groups upon boost vaccination (day 21), no pig had 
developed homologous HI antibodies with a titer higher than 20. On day 27, all doses (5×106 
IU, 106 IU and 5×105 IU) induced HI antibodies against homologous virus; geometrical titer 
means of each group were at least 160 (Figure 2A). On day 40, HI titers of all H3N2 RP 
vaccinated groups decreased, but fourteen of fifteen pigs had HI titers at least 40. The H3-
5e6 group HI titer (mean titer: 121) was significantly greater than the other 2 groups (Figure 
2A). HI titers against delta1 virus were tested on serum samples from H3-e6 and H3-5e5 
vaccinated groups on day 40. No pigs in H3-5e6 or H3-5e5 vaccinated group developed 
detectable HI antibodies against delta1 strain (data not shown).   
In delta1 RP vaccinated groups against a homologous or heterologous δ1 strain in the 
same cluster, δ1-e7 and δ1-5e6 groups developed HI antibodies with means titer ≥46, while 
δ1-e6 (mean titer: 20) and δ1-5e5 (mean titer: 11) groups developed lower HI antibodies 
titers against homologous strain or heterologous δ1 strain (Figure 2B). HI antibodies, induced 
by all doses of delta1 RP, had poor cross-reactivity with delta2 sub-cluster with mean titers 
all below 10 (Figure 2B). A linear regression exists between delta1 RP doses (x) and 
transferred HI titers against homologous strain (y): y = 0.1274x + 1.6099. R² = 0.5994 
(Appendix 1). 
Pathological evaluation 
Upon macro-pathological examination, all pigs (n=10) vaccinated with H3N2 RP 
developed lung lesions. Mean of H3-e6 group was 9.2±1.2 and mean of H3-5e5 group was 
75 
12±3.9. Three of five pigs in δ1-e6 group (5.2±2.6), and only one of four pigs in δ1-5e5 
group (4.8±4.8) developed lung lesions (figure 3A; Appendix 2). In HE staining, all pigs, 
except one in δ1-e6 group, were observed to possess histopathological lesions with different 
severity (Appendix 2). Mean of HE scores of H3-5e6 group was 1.8±0.2, H3-5e5 group was 
2±0.2, δ1-e6 group was 1.3±0.4 and δ1-5e5 group was 1.5±0.5 (figure 3B). However, in IHC 
staining, two of five samples in H3-5e5 group (0.4±0.2), only one of five samples in each of 
H3-e6 group (0.2±0.2) and δ1-e6 group (0.2±0.2) were observed with strained virus in lung 
tissues, while virus was not observed in any of the four samples in δ1-5e5 group (figure 3C; 
Appendix 2). 
In macro-pathological scores and HE scores, delta1 RP vaccinated groups had lower 
means than groups vaccinated with H3N2 RP. In IHC scores, groups vaccinated with delta1 
RP had mean scores at the same or lower levels than H3N2 group. Higher doses of H3N2 RP 
vaccination resulted in lower lung lesion scores with all staining methods after delta1 
challenge. However, none of these differences were statistically significant (Figure 
3A,B&C). 
Discussion 
The RP system can be employed to express variant HA proteins of influenza strains 
from field isolates (Vander Veen et al., 2012b). This study provides an efficacy parameter 
indicating the lowest efficient dose of RP-expressing HA genes from different influenza 
strains. These finding will aid in determination of the dose of RP needed in future studies. 
With 5×105 IU of RPs expressing different HAs (H3N2 or delta1), nine of ten pigs tested had 
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homologous HI titer of as least 40 on day 27, and eight of nine pigs had detectable 
homologous HI antibodies (≥20) on day 40. Virus replication in lungs was completely 
inhibited in pigs vaccinated by 5×105 IU delta1 RP at 5 dpc and lung lesions were reduced 
compared with control pigs. Thus 5×105 IU was a sufficient dose to eliminate virus 
replication in pigs. In addition, this is the first reported study to evaluate efficacy of delta1 
RP in protecting pigs against homologous challenge. In contrast to a high dose (108 IU) used 
in previous studies to evaluate HA RP protection efficacy (Vander Veen, 2011;Vander Veen 
et al., 2012b), this study demonstrates a much lower dose of RP that still provides protection 
to pigs, which shows the strong immunogenicity of RP based IAV vaccines. In addition, the 
serological results show antibodies induced by delta1 RP have robust cross-reactivity with 
heterologous strain within the same sub-cluster. 
Clinical syndromes and rectal temperatures, of pigs experimentally challenged with 
IAV were not significantly different from non-challenged pigs in this study and in other 
experimental challenge studies (Ma et al., 2011;Vincent et al. 2008b). Therefore, whether 
homologous RP vaccine significantly prevented influenza clinical syndromes in pigs was not 
demonstrated in this study. However, in a previous study, H3 RP was shown to reduce fever 
significantly compared with non-vaccinated pigs following homologous challenge (Vander 
Veen et al., 2012b).  
With the presence of HI antibodies with mean titer equal or lower than 20, virus 
replication in lungs was completely inhibited at 5 dpc, however, pneumonia was not. In 
chapter 3, following one dose IM vaccination with RP, virus replication was inhibited in the 
presence of low HI titer prior to challenge, agreeing with this study. It was previously 
77 
reported that high titers of homologous HI antibodies (titer> 100) completely inhibit virus 
replication (Heinen et al., 2001; Wesley et al., 2004; Vander Veen et al., 2009). Here, we 
reported that HI titer of 20 or lower inhibits virus replication as well. The capacity of the RP 
vaccine to stimulate memory T cells has been shown in Vander Veen et al. (2011). Memory 
cells circulating in serum may be stimulated by antigens rapidly. Thus, a high HI titer may 
not be necessary to prevent homologous influenza infection in pigs. 
Following two IM vaccinations, all doses of H3N2 RP evaluated in this study were 
sufficient to induce high titers (≥160) of homologous HI antibodies on day 27 and the 
antibodies lasted at least until day 40. For delta1 RP, by rising the vaccine dose, HI antibody 
titer could be increased and there was a linear regression relationship observed between the 
dose and the titer. In contrast, circulating HI antibodies against H3 antigen upon challenge, 
did not have measurable cross-reactivity with challenge virus in HI assay. However, all 
pathological scores in H3-e6 group were lower than H3-5e5 group. Gauger et al. has shown 
that inactivated delta1 vaccine enhanced disease including pneumonia and clinical syndromes 
following H1 homosubtypic, heterologous pandemic H1N1 challenge (Gauger et al., 2011). 
Vincent et al. showed inactivated classical H1N1 vaccine enhanced pneumonia following 
delta1 challenge (Vincent et al., 2008b). There was no cross-reaction between the vaccine-
induced HI antibodies to challenge antigen, when pneumonia was enhanced in the study by 
Gauger et al. (2011). In contrast, commercial multivalent vaccine-induced HI antibodies 
which had low or unmeasurable reactivity to challenge antigen, but provided partial 
heterologous protection to pandemic H1N1 challenge (Vincent et al., 2010). Therefore, 
cross-reactivity of HI antibodies may not indicate the cross protection efficacy of vaccines. In 
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addition, modified live virus vaccine did not enhance disease, but provided partial protection 
to heterologous challenge (Vincent et al., 2007). Because of the lack of a non-vaccinated 
challenge group as a control, whether H3N2 RP reduced or enhanced disease severity could 
not be demonstrated. Evaluating whether RP based vaccine protects heterologous strain 
challenge in vivo in future studies will help to estimate the risk of RP vaccine when the RP 
vaccine is a mismatch with the challenge virus. It will also help to determine whether the 
disease enhancement by mismatch vaccine is related to virus strains, certain virus proteins or 
vaccine types.  
To conclude, this study shows that prime/boost RP at 5×105 IU or higher doses tested 
were sufficient to induce detectable HI antibody. HI titers could be increased by increasing 
vaccine doses. Delta1 RP at 106 IU and 5×105 IU, which induced HI antibodies with mean 
titers equal to or lower than 20, partially protected homologous infection by eliminating virus 
replication in lungs at 5dpc. However, compared with H3N2 RP vaccinated pigs, decreased 
lung lesions observed in delta1 RP vaccinated pigs were not statistically significant. 
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Table 1. Animal study protocol 
Group 
name  
Pig 
numbers  
HA subtype 
expressed by 
RP1  
RP Dose2 Challenge3 Euthanasia day 
H3-5e6 5 Cluster IV 
H3N2 
5×106 IU  42 
H3-e6 5 1×106 IU × 47 
H3-5e5 5 5×105 IU × 47 
δ1-e7 5 
Delta 1 
huH1N2 
1×107 IU  42 
δ1 -5e6 5 5×106 IU  42 
δ1-e6 5 1×106 IU × 47 
δ1−5e5 5 5×105 IU × 47 
1
 Each pig received the same vaccine intramuscularly in both prime and boost vaccination. 2 
Each dose was in 2ml volume administered intramuscularly. 3 All challenged pigs were 
challenged on day 42 with the same virus homologous to δ1 RP. 
 
 
Figure 1. Virus isolation titers from BAL samples at 5 dpc, different characters representing significant differences.  
 
 
 
a
4.05
a
4.5
b
0
b
0
0
1
2
3
4
5
6
H3 e6 H3 5e5 Delta1 e6 Delta1 5e5V
ir
u
s 
ti
te
r 
(L
o
g
1
0
x
 T
C
ID
5
0
/
m
l)
Vaccine Treatment
Virus isolation from BAL
Figure 2. (A) HI titers of H3N2 RP vaccinated groups against homologous H3N2 antigen, different characters 
representing significant differences, uppercase characters representing day 27 and lowercase characters representing 
day 40; (B) HI titers of serums samples from 
homologous delta1 antigen; hetero d1: heterologous delta1 antigen; d2: heterologous delta2 antigen.
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delta1 RP vaccinated groups on day 40 against different antigens. Homo: 
  
256
144
288
36
176
50
day 27 day 40
H3-5e6
H3-1e6
H3-5e5
h
o
m
o
 
h
et
er
o
 d
1
d
2
h
o
m
o
 
h
et
er
o
 d
1
d
2
h
o
m
o
 
h
et
er
o
 d
1
Delta 1 (5e6) Delta 1 (1e6) Delta 1 (5e5)
46
70
2
20 19
1 11
20
 
 
d
2
1
Figure 3. Different characters representing significant diffe
group; (B) means of HE lesion scores of each group; (C) means of IHC scores of each group.
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rences. (A) Means of macro-pathological scores of each 
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CHAPTER 5. GENERAL CONCLUSIONS 
Various methods of vaccination of pigs for influenza A virus (IAV) were reviewed. 
Currently, there are two vaccination schemes can be used for protection against IAV. These 
are USDA licensed commercial vaccine and USDA licensed autogenous vaccines. Since it 
takes over one year to change the subtypes present in a commercial vaccine, the autogenous 
vaccine which can be produced within 3 to 4 months currently offers an alternative 
vaccination method. However, the USDA does not require efficacy or potency to be 
conducted with autogenous vaccines.  
Different administering routes with IAV replicon particle (RP) have been tested. 
Significant protection was provided by one dose intramuscular (IM) RP vaccination. The 
result also demonstrated that the protection provided by RP was induced as early as three 
weeks post prime vaccination. Intranasal/IN administering RP did not protect pigs against 
homologous IAV challenge. A different method of aerosolization or nebulization RP droplet 
may results in better protection.  
Herein, studies were conducted for the first time with a RP prepared against IAV 
delta1 sub-cluster. Three doses were compared, and the lower dose of 5×105 IU RP partially 
protected pigs. In addition, it was found that 5×105 IU RP induced hemagglutinin (HI) 
antibodies with a mean titer lower than 20, and with the presence of such level of HI 
antibodies, virus replication was inhibited in pigs. 
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APPENDIX 1 
Linear regression of delta1 RP doses (x-axis) and modified HI titers* (y-axis) against homologous δ1 antigen.  
  
* Transferred HI titer= log2 (2z/10); z=original HI titer. ** 5×105 IU was defined as one 
dose.
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APPENDIX 2 
A summary of pathological scores and virus isolation titers of each pig of studies of Chapter 4 
Vaccine 
Heterologous 
delta 1 HI titer 
(day of challenge) 
Macro-
pathological 
Score 
HE 
score  
IHC 
Score 
BAL virus 
titer 
H3 (1e6) Neg 9 1 0 3.75 
H3 (1e6) Neg 10 2 1 4.75 
H3 (1e6) Neg 8 2 0 4.5 
H3 (1e6) Neg 13 2 0 3.75 
H3 (1e6) Neg 6 2 0 3.5 
H3 (5e5) Neg 3 2 1 4.5 
H3 (5e5) Neg 26 2.5 1 3.25 
H3 (5e5) Neg 10 1.5 0 4.75 
H3 (5e5) Neg 7 1.5 0 5.5 
H3 (5e5) Neg 14 2.5 0 4.5 
Delta (1e6) 40 4 1 0 0 
Delta (1e6) Neg 9 2.5 0 0 
Delta (1e6) 40 13 2 1 0 
Delta (1e6) 20 0 1 0 0 
Delta (1e6) 80 0 0 0 0 
Delta (5e5) 20 19 3 0 0 
Delta (5e5) 20 0 1 0 0 
Delta (5e5) 20 0 1 0 0 
Delta (5e5) 20 0 1 0 0 
 
